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Gene therapy with viral vectors is a 
promising new treatment option for 
heart diseases. However, none of the 
current cardiovascular gene therapy ap-
plications have progressed to the clini-
cal use due to low efficiency. The aim 
of this thesis was to develop a clinically 
relevant intramyocardial gene transfer 
method for mice and to apply the method 
to evaluate the efficiency and safety of 
gene transfer with adenovirus-, adeno-
associatedvirus- and lentivirus vectors 
as well as the angiogenic potency of dif-
ferent vascular endothelial growth fac-
tors in the heart. To further develop the 
methodology for mouse cardiac studies, a 
mouse electrocardiogram analysis algo-
rithm was developed and validated. 
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ABSTRACT 
 
Cardiovascular diseases are the leading global cause of death. Gene therapy is a promising 
new treatment option for heart diseases and viral vectors are used for delivering therapeutic 
genes into the myocardium. Vascular endothelial growth factors (VEGFs) are among the 
most powerful factors regulating vascular growth, making them potential candidates for 
angiogenic gene therapy. Adenoviruses (AdVs) and adeno-associated viruses (AAVs) have 
been the two vectors most widely used for gene delivery to the heart, whereas lentiviral (LeV) 
vectors have not been extensively evaluated. Mouse models are extremely important in 
studying cardiac diseases and the related electrophysiological measurements.  
The aim of this thesis was to develop a clinically relevant high-resolution 
echocardiography-guided closed-chest intramyocardial gene transfer method for mice and 
to evaluate the angiogenic potency and safety of adenovirally delivered VEGF-A, -B and-E. 
In addition, the effects and safety of intramyocardial gene transfer of AdV-, AAV- and LeV 
vectors were studied. A mouse electrocardiogram (ECG) analysis program was developed 
and validated to be used in future mouse cardiac studies. 
With the novel closed-chest intramyocardial injection method, the VEGF-R1-specific 
ligand VEGF-B and the VEGF-R2-specific ligand VEGF-E were firstly compared to VEGF-A, 
which stimulates both receptors, with respect to their effects on angiogenesis and left 
ventricular function. Secondly, the same method was applied to compare AdV vectors to 
AAV2-, AAV9- and LeV vectors in mouse heart with regard to the transduction efficiency, 
myocardial damage, effects on the left ventricular function and ECG. AAV9 was also tested 
by using i.v. injections of three different virus doses. The third study utilized the newly 
developed mouse ECG analysis system to examine the effects of ageing, pharmacological 
manipulations (with atropine, metoprolol and verapamil), acute myocardial infarction (AMI) 
and progressive left ventricular hypertrophy (LVH) on mouse ECG.  
AdV VEGF-B and AdV VEGF-E were found to be equally potent in inducing therapeutic 
angiogenesis in mouse myocardium and they caused fewer side effects than AdV VEGF-A.  
Left ventricular function, measured by ejection fraction, did not change during the follow-up 
of two weeks. Compared to the widely used AdV vector, AAV2, AAV9 and LeV were less 
effective in transducing cardiomyocytes, but also less inflammatory. Local administration of 
AAV9 was more efficient and safer than systemic delivery. Ageing, drug administrations, 
AMI and LVH evoked similar ECG and echocardiographic changes in mice as seen in 
humans. These results will be beneficial in studying the cardiac pathologies and novel 
therapies in mice and hopefully in translating these preclinical results into breakthroughs in 
the therapy of human cardiac diseases. 
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TIIVISTELMÄ 
 
Sydän- ja verisuonisairaudet ovat johtava kuolinsyy maailmanlaajuisesti. Geeniterapia on 
lupaava uusi hoitomuoto sydänsairauksille ja virusvektoreita käytetään terapeuttisten 
geenilääkkeiden kuljettimina sydänlihakseen. Verisuonen endoteelin kasvutekijät (VEGF) 
ovat voimakkaita verisuonten kasvuun vaikuttavia tekijöitä ja siten potentiaalisia uusia 
lääkkeitä käytettäväksi verisuonten uudismuodostukseen tähtäävässä geeniterapiassa. Tällä 
hetkellä adenovirukset (AdV) ja nyttemmin myös adeno-assosioituvat virukset (AAV) ovat 
käytetyimpia virusvektoreita sydämen geeninsiirrossa, sen sijaan lentivirusvektoreita (LeV) 
ei ole paljoa tutkittu tässä yhteydessä.  
Tämän väitöskirjatutkimuksen tavoitteena oli kehittää kliinisesti relevantti 
ultraääniohjattu sydämensisäinen geeninsiirtomenetelmä hiirille ja arvioida sen avulla 
adenovirusvälitteisesti siirrettyjen VEGF-A, -B ja –E –kasvutekijöiden potentiaalia 
uudisverisuonimuodostuksen ja turvallisuuden kannalta. Halusimme niinikään tutkia AdV-
, AAV- ja LeV-virusvektoreiden tehoa ja turvallisuutta. Kehittääksemme edelleen hiiren 
sydäntutkimusmenetelmiä, kehitimme ja validoimme hiiren elektrokardiogrammi (EKG)-
analyysiohjelman. 
Uuden ultraääniohjatun sydämensisäisen geeninsiirtomenetelmän avulla vertasimme 
VEGF-R1 spesifistä ligandia VEGF-B:tä ja VEGF-R2-spesifistä ligandia VEGF-E:tä VEGF-
A:han, joka stimuloi molempia reseptoreita, tutkimalla niiden angiogeneettistä potentiaalia 
ja vaikutuksia sydämen toimintaan. Samalla menetelmällä vertailtiin AdV, AAV2, AAV9 ja 
LeV vektoreita geeninsiirtotehokkuuden, kudostuhon ja sydämen toiminnan suhteen. 
AAV9-vektoria tutkittiin myös systeemisen annon jälkeen. Kolmanneksi, analysoimme 
kehittämämme hiiren EKG-analysointiohjelman avulla, mitä muutoksia ikääntyminen, 
farmakologiset manipulaatiot (atropiinin, metoprololin ja verapamiilin avulla), akuutti 
sydäninfarkti ja progressiivinen vasemman kammion hypertrofia aiheuttavat hiiren EKG:iin. 
Havaitsimme, että VEGF-B ja VEGF-E olivat yhtä hyviä aiheuttamaan terapeuttista 
verisuonten uudismuodostusta hiiren sydämessä ja ne aiheuttivat vähemmän 
sivuvaikutuksia kuin VEGF-A. Sydämen toiminta ei muuttunut kahden viikon 
seurantajakson aikana. Verrattuna paljon käytettyyn AdV-vektoriin, AAV2-, AAV9- ja LeV-
vektoreilla ei ollut yhtä hyvä geeninsiirtotehokkuus, mutta ne olivat toisaalta turvallisempia. 
Sydämeen tehty geeninsiirto AAV9-vektorilla oli tehokkaampi ja turvallisempi systeemiseen 
geeninsiirtoon verrattuna. Ikääntyminen, lääkkeet, sydäninfarkti ja vasemman kammion 
hypertrofia johtivat samanlaisiin EKG-muutoksiin hiirillä kuin ihmisillä. Tulokset auttavat 
sydänsairauksien ja terapeuttisten sovellusten tutkimisessa erilaisissa hiirimalleissa. 
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1 Introduction  
Cardiovascular diseases, especially ischemic heart disease, are the most common cause of death 
all around the world (Lozano et al. 2012). Current treatment strategies for coronary artery disease 
(CAD) include medication and lifestyle changes but more advanced disease requires more 
invasive approaches, i.e. balloon angioplasty with stenting or bypass surgery. However, these 
conventional therapies cannot be performed in all patients, e.g. elderly patients and patients with 
diffuse CAD of small vessels are not suitable candidates. Therefore, there is an obvious need to 
develop efficient and minimally invasive treatment strategies for these no-option patients 
(Halonen et al. 2014). 
Gene therapy is a promising novel treatment modality for cardiac diseases and it has displayed 
good potential and efficacy in preclinical trials (Yla-Herttuala 2013). The most common approach 
in cardiac gene therapy has been to induce therapeutic angiogenesis to increase blood flow within 
the ischemic myocardium. In cardiovascular clinical trials, these gene therapies have displayed 
excellent safety profiles, even in long-term follow-up, but their efficacy has been far from optimal 
(Halonen et al. 2014, Yla-Herttuala 2013, Hedman, Hartikainen & Yla-Herttuala 2011). 
An efficient and clinically applicable gene delivery system is a fundamental part of any 
successful cardiac gene therapy (Katz et al. 2012). Local gene transfer techniques are clearly more 
efficient than systemic delivery i.e. intra-arterial (ia) or intravenous (iv) administrations (Yla-
Herttuala 2013, Rissanen, Yla-Herttuala 2007). The traditional open-chest intramyocardial gene 
transfer is associated with serious traumatic damage, whereas percutaneous intramyocardial 
gene transfer with intracardiac catheters causes much more modest side effects (Katz et al. 2013). 
In addition, an efficient gene transfer vector is a prerequisite for effective gene therapy. At 
present, the highly efficient adenovirus (AdV) vectors, which cause a short peak of transgene 
expression, have been the most widely used vectors in cardiac gene therapy. In addition, adeno-
associated virus (AAV) vectors are promising gene delivery vectors since they can achieve long-
term transgene expression, lasting for several months. Lentivirus (LeV) vectors can provide a 
lifelong expression of the therapeutic protein in the target cells but they have not been widely 
used for cardiac gene therapy. (Katz et al. 2013, Giacca, Zacchigna 2012.) 
The mouse has become an increasingly important species when devising models of cardiac 
diseases mainly because of the ever-expanding number of genetically modified mice (Scherrer-
Crosbie, Thibault 2008). Due to small size of the animal, it has been challenging to measure the 
clinically relevant physiological parameters needed to reveal the disease mechanism and to 
extrapolate the results to the therapies of human cardiac diseases. 
The aim of this thesis was to develop a clinically relevant high-resolution echocardiography-
guided closed-chest intramyocardial gene transfer method for mice and to evaluate the effects 
and safety of intramyocardial gene transfer of AdV-, AAV- and LeV vectors and furthermore to 
assess the angiogenic potency and safety of adenovirally delivered vascular endothelial growth 
factor (VEGF)-A, -B and-E growth factors. To further develop the methodology for mouse cardiac 
studies, a mouse electrocardiogram (ECG) analysis algorithm was developed and validated by 
examining the ECG findings associated with ageing, pharmacological manipulations, acute 
myocardial infarction (AMI) and progressive left ventricular hypertrophy (LVH). 
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2 Review of the Literature 
2.1 CARDIOVASCULAR SYSTEM 
2.1.1 Heart and circulation 
The circulation serves the needs of the body and maintains an optimal environment in all tissue 
fluids by delivering oxygenated blood from the lungs to the rest of the body and returning the 
oxygen-poor and carbon dioxide-rich blood back to the lungs where the gases are exchanged. The 
circulation also transports other nutrients and hormones to tissues and takes waste products 
away from the tissues to the lungs, liver and kidneys. (Guyton, Hall 2006.) 
The heart is the central part of the circulatory system; it is the tissue that ensures that there is 
an optimal blood pressure and blood flow. The cardiac cycle consists of a relaxation period called 
diastole when the heart fills with blood and a period of contraction called systole when the heart 
expels the blood. The heart is composed of two pumps separated by the interventricular septum; 
the right heart that pumps blood via the pulmonary artery to the pulmonary circulation and the 
left heart that pumps blood via the aorta to the systemic circulation and peripheral organs. Both 
right and left sides of the heart have an atrium and a ventricle. (Figure 1.)  Blood flows from the 
great veins into the atria and about 80 % of the blood flows passively from atria into the ventricles 
after which the atria contract and cause an additional 20 % filling of the ventricles. Therefore, the 
atria function as a weak primer pump for the ventricles although it is the ventricles that supply 
the main pumping force for the blood. (Guyton, Hall 2006.) 
The atrioventricular valves, namely the tricuspid and mitral valves, close passively during 
systole and prevent backflow of blood from the ventricles to the atria. Instead, the semilunar 
valves i.e. the aortic and pulmonary artery valves are passively closed during diastole ensuring 
that there is no backflow from the aorta and pulmonary arteries. The valves also open passively 
when a forward pressure gradient forces blood through the valves during systole (the semilunar 
valves) and diastole (the atrioventricular valves). (Guyton, Hall 2006.) 
 
 
Figure 1. Structure of the heart and the direction of blood flow through the heart chambers and heart 
valves. (Courtesy of Wikipedia.org, used under license.) 
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Figure 1. Structure of the heart and the direction of blood flow through the heart chambers and heart 
valves. (Courtesy of Wikipedia.org, used under license.) 
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The heart pumps blood first through the large elastic arteries with strong vascular walls 
comprising intimal, medial and adventitial layers divided by the internal and external elastic 
laminas. The arteries branch into smaller arterioles, which subdivide further into the terminal 
arterioles and finally into capillaries (Kumar, Abbas & Fausto 2005). The arterioles have a strong 
muscular wall, which can constrict or dilate the arteriole thereby altering significantly the blood 
flow in response to the needs of the tissue (Guyton, Hall 2006). 
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exchange fluids, nutrients, electrolytes, hormones and other substances between blood and the 
interstitial fluid of the tissues. The length of a capillary is about 0.3-1 mm and they are 4-9 µm in 
diameter, just enough to allow red blood cells to passage through the vessels. The capillary walls 
consist of a monolayer of endothelial cells (ECs) surrounded by a basement membrane and 
covered by scattered pericytes. (Guyton, Hall 2006.) 
The oxygen-poor and CO2-rich blood from capillaries is collected by the post-capillary venules, 
through the vessel walls which also permit leukocyte infiltration into the tissues. These venules 
drain into larger muscular venules in which the pericyte coverage is replaced by a continuous 
smooth muscle cell (SMC)-layer. Although the SMC-layer is thinner than that of the arterioles, 
muscular venules are also capable of contracting due to their low blood pressure. These vessels 
gradually merge into the larger veins and transport blood back to the heart. Veins also serve as a 
major reservoir of extra blood i.e. about 64 % of the circulating blood is located in the veins at any 
given time. (Guyton, Hall 2006.) 
2.1.2 Cardiac circulation 
 
The cardiac muscle, the myocardium, receives blood from the coronary arteries which are 
situated circularly around the heart. The coronary circulation differs from other tissues in the 
sense that the circulation happens mostly in diastole, when the cardiac muscle relaxes and does 
not obstruct blood flow through the left ventricle (LV) capillaries, as occurs in systole. At rest, the 
cardiac circulation accounts for about 4-5 % of the cardiac output (i.e. the total volume of blood 
pumped by the LV every minute), but during intense exercise when the cardiac muscle’s need 
for nutrition is elevated, the coronary blood flow increases up to fourfold due to arterial 
vasodilatation and the greater cardiac output. (Guyton, Hall 2006.) 
The coronary artery circulation arises from two principal coronary arteries, the left main (LM) 
coronary artery and the right coronary artery (RCA), which both arise from the aorta immediately 
above the aortic valve (Figure 2). The LM branches to the left anterior descending artery (LAD) 
which travels through the anterior surface of the heart on top of the interventricular septum. The 
length of the LAD varies; the shorter vessels do not extend to the apex and the longer vessels go 
around the apex. The left circumflex artery (LCX) travels in the sulcus between the left atrium 
and ventricle and RCA passes into the sulcus between the right atrium and ventricle giving rise 
to the posterior descending artery (PDA) in 90 % of human hearts although in the remaining 10 
% of humans the PDA originates from LCX. The LM distributes blood mainly to the anterior and 
left lateral portions of the LV and the RCA supplies blood to the most of the right ventricle and 
the posterior part of the LV. The larger arteries branch many times, giving rise to a dense network 
of capillaries. (Guyton, Hall 2006, Katz 2006.) The anatomy of the coronary circulation varies 
between individuals and species; in mice, the variability between different strains and 
individuals is even higher than in humans.  In humans, the three main coronary arteries (LAD, 
LCX and RCA) lie epicardially on the surface of the heart and give rise to smaller branches that 
penetrate into the myocardium (Heikkilä et al. 2008). Instead, in mice the coronary arteries are 
intramyocardial and the visible vessels are cardiac veins (Treuting, Dintzis 2012). However, in 
general, the anatomy of the coronary artery in mice is comparable to that found in humans 
(Gehrmann et al. 2001). 
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Figure 2. Coronary arteries (courtesy of Wikipedia.org, used under license).  
 
 
Most of the coronary venous blood from the LV muscle returns to the right atrium through the 
coronary sinus, which runs transversely in the left atrioventricular groove on the posterior side 
of the heart, and most of the coronary venous blood from the right ventricular muscle returns 
through small anterior cardiac veins which flow directly into the right atrium (Guyton, Hall 2006). 
In humans, as well as in some other mammals, there are small anastomotic channels, known 
as collateral arterioles, which interconnect the epicardial coronary arteries. In a normal heart, they 
are poorly developed, but the development of large collaterals is of major importance, for 
example in a heart with CAD when the major coronary arteries have become obstructed (Guyton, 
Hall 2006). The collateral arteries provide an alternative source of nutrition to the myocardium 
which is not receiving an adequate blood supply due to the occlusive CAD, and they can help to 
preserve myocardial function, thereby having a relevant protective role in CAD patients. After 
coronary occlusion, collateral blood flow may be sufficient to maintain myocardial viability at 
rest in some patients, but it is thought that the collateral circulation is usually not sufficient to 
meet myocardial demands during times of higher oxygen demand, such as during exercise, and 
may not prevent myocardial ischemia after coronary occlusion. (Meier et al. 2013, Seiler et al. 
2013.) Collateral growth occurs via a process called arteriogenesis, which will be discussed later.  
2.1.3 Anatomy and physiology of cardiac muscle 
There are three major types of cardiac muscle: atrial and ventricular muscle fibers, which contract 
rather similarly to skeletal muscle, and the specialized excitatory and conductive muscle fibers 
that contract only weakly but instead make up the conduction system of the heart (Guyton, Hall 
2006).  
The cardiac muscle fibers are arranged in a latticework; the fibers divide, recombine and then 
spread again. Similarly to the situation in skeletal muscle, cardiac muscle is striated and has 
myofibrils that contain actin and myosin filaments lying side by side so that they can slide along 
each other during contraction. Cardiomyocytes are connected via intercalated discs to each other 
with each cardiomyocyte being connected to at least two other cardiomyocytes in series and in 
parallel with at least one other cardiomyocyte. The intercalated discs contain permeable gap 
junctions, composed of connexin proteins, which allow almost totally free diffusion of ions 
enabling a very fast spread of action potentials during depolarization (Guyton, Hall 2006, 
Heikkilä et al. 2008). Cardiomyocytes have one or more nuclei although there are variations 
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between species; in humans over 75 % of cardiomyocytes have only one nucleus, instead in mice 
over 75 % of cardiomyocytes have two nuclei (Treuting, Dintzis 2012). 
2.1.4 Cardiac conduction system 
The heart has a specialized excitatory and conductive system that controls cardiac contractions 
(Figure 3). The normal rhythmical impulse is generated in the sinoatrial node (sinus node or S-A 
node), which is situated in the superior posterolateral wall of the right atrium below the opening 
of the superior vena cava. The S-A node is composed of specialized cardiac muscle which has the 
capability of self-excitation and it is connected to the atrial muscle fibers enabling the action 
potential to spread promptly from the S-A node into the atrial muscle wall. From the S-A node, 
the impulse is conducted rapidly to the A-V node via the anterior, medial and posterior 
internodal pathways and via Bachmann´s bundle to the left atria. The impulse is delayed in the 
A-V node before it passes into the ventricles depending on the HR and autonomic nervous 
system; increased heart rate (HR) shortens and vagal effect increases the delay. In addition, there 
is fibrous tissue surrounding the A-V valvular openings that separates the atria from the 
ventricles, normally inhibiting the conduction of action potentials directly from the atria to the 
ventricles, instead, they are conducted via the A-V bundle. This separation allows the atria to 
contract a short time before the ventricular contraction, which is important to ensure effective 
functioning of the heart. From the A-V node, the impulse is conducted via the bundle of His and 
the left and right bundle branches of Purkinje fibers; this process occurs within a few milliseconds 
to all parts of the ventricles. (Guyton, Hall 2006, Heikkilä et al. 2008.) Currently it is not clear 
whether mice have a true Bachmann´s bundle, but otherwise mice do not exhibit any major 
differences in cardiac conduction system compared to humans (Kaese, Verheule 2012, Miquerol 
et al. 2004, Rentschler et al. 2001, VanderBrink et al. 1999). However, unlike in the human heart, 
in the mouse the ventricular myocardium at the basal septum is in direct contact with the His 
bundle. This is thought to be caused by less fibrous insulation and as a result, the onset of 
ventricular activation occurs at the top of the septum and not on the left side of the septum, as in 
humans. (Boukens et al. 2014.) 
 
 
Figure 3. Conduction system of the heart. Modified from: https:// 
classconnection.s3.amazonaws.com/754/flashcards/2034754/png/ch_9_pic_141349381898638.png” 
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Myocardial electrical activity happens in the form of action potentials (APs), which are changes 
in the membrane potential associated with the depolarization of the cell membrane. APs are 
generated due to activation and inactivation of depolarizing (Na+, Ca2+) and repolarizing (K+) 
current channels. The conduction and propagation of electrical activity through the myocardium 
depend on electrical coupling between the cells, which is mediated by gap junction channels. 
(Nerbonne 2004.) Depolarization and repolarization are qualitatively similar in the human and 
mouse myocardium, but there are marked quantitative differences in electrical properties (Kaese, 
Verheule 2012, Liu et al. 2004). In addition, the HR of an adult mouse at rest is 500-725/min, which 
is about 10 times faster than in the normal adult human heart (Kaese, Verheule 2012, Nerbonne 
2004). The duration of the AP increases with body size; in the mouse ventricle it is approximately 
50 ms compared to the human value of 250 ms (Kaese, Verheule 2012). 
In the resting state, the cell membrane of a cardiomyocyte is electrically polarized such that 
the intracellular space is negatively charged in comparison to the extracellular space making the 
membrane potential negative. Membrane potential is created because of the different ion 
concentrations inside and outside the cell; the potassium concentration inside the cell is about 30 
times higher compared to extracellular space and the ratio is opposite with sodium ions. The AP 
causes the membrane potential to rise from the resting negative value of -90 mV to a slightly 
positive value of about 20-30 mV during each cardiac beat. (Guyton, Hall 2006, Heikkilä et al. 
2008.) 
In both mice and humans, the ventricular APs consist of a fast depolarizing phase, the AP 
upstroke, which reflects the inward current through the voltage-gated sodium channels (Figure 
4). The repolarization is different in these two species (Kaese, Verheule 2012, Nerbonne 2004). In 
humans, when the membrane potential reaches a positive value of 30 mV during the AP upstroke, 
the sodium channels are closed and the membrane potential slightly decreases to about zero and 
remains at that value. This prolonged period of depolarization is called the plateau phase of the 
AP and it is generated by the slow sodium-calcium channels, which enable the influx of sodium 
and calcium ions and at the same time there is outflow of potassium ions followed by the release 
of the sarcoplastic calcium ions. The AP plateau phase ends when the slow sodium-calcium ion 
channels are inactivated. When the membrane potential decreases to -50 mV, the potassium 
outflow increases, resulting in a second rapid phase of repolarization and thus in the return of 
the membrane potential to its resting value of -90 mV. (Guyton, Hall 2006, Heikkilä et al. 2008.)  
In mice, the AP is triangular in shape, since the upstroke is followed by a rapid downstroke. 
There is no distinctive plateau phase seen and no subsequent distinct time point of repolarization 
but, instead a continuous phase of repolarization. (Boukens et al. 2014, Kaese et al. 2013.)  This is 
because different ion currents are responsible for the AP shape in humans and mice (reviewed 
by Nerbonne, Kass 2005).  
In the plateau phase the increased calcium concentration triggers the attachment of calcium 
ions to troponin C, a contractile protein within the sarcomeres. This leads to sliding of the myosin 
between actin causing the sarcomere to shorten and the muscle to contract. The separation of 
calcium ions from troponin C ends the mechanical work of the sarcomere. During  repolarization, 
the intracellular sodium, potassium and calcium ion concentrations return to their levels in the 
resting state. This is due to a reduction in the amount of intracellular calcium ions mediated by 
the sodium-potassium exchanger and the activation of calcium pumps in the sarcoplastic 
reticulum (SERCA2 pumps), which transport calcium ions into intracellular storage vesicles. 
(Guyton, Hall 2006, Heikkilä et al. 2008.) 
The electrical stimulus leading to contraction of the cardiac muscle begins from the cells in the 
S-A node, which are capable of depolarizing spontaneously. In addition, His-Purkinje fiber cells 
and in abnormal conditions also some other cells, for example the A-V nodal cells and the atrial 
internodal fiber cells have this ability. The spontaneous diastolic depolarization is repeated 
regularly according to intrinsic HR, which determines the basal HR. Depending of the status of 
the autonomic nervous system, the S-A node fires at a rate of 40-100 bpm in humans, most 
commonly the HR is 60-70 bpm (Heikkilä, Mäkijärvi 2003). As stated above, in conscious mice 
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the resting HRs vary between 500 and 725 bpm (Kaese, Verheule 2012). The cardiomyocytes in 
the S-A and A-V nodes have a different kind of AP compared to normal ventricular 
cardiomyocytes. They are called slow APs, which have smaller membrane potential at rest and 
during AP, slower upstroke phase and slow conduction rate making the AP waveform look 
different. (Heikkilä, Mäkijärvi 2003.) 
 
 
Figure 4. The action potentials of human (left) and murine (right) ventricular myocytes in relation to 
the species-spesific patterns on the ECG. In the schematic representation of action potentials, the 
myocardium activated earliest is presented with continuous line and the myocardium activated latest 
is presented with dashed line. Modified from Boukens (Boukens et al. 2014).  
 
  
AP waveforms and conduction can change significantly in the diseased myocardium due to 
changes in the expression of ion channels, which can lead to desynchronization and arrhythmias 
(Nerbonne 2004). 
2.1.5 Electrocardiogram 
The electrocardiogram (ECG) displays the P, Q, R, S and T waves (Figure 5), which are electrical 
voltages generated by the heart and recorded by the electrocardiograph from the surface of the 
body. Mouse ECG differs from human ECG in certain aspects. In human and mouse heart, the 
spread of depolarization through the atria causes the P wave, after which the atria contract. 
(Guyton, Hall 2006, Kaese, Verheule 2012.) Sometimes the mouse P wave is followed by a small 
negative deflection, which is proposed to either represent atrial repolarization (Speerschneider, 
Thomsen 2013) or to occur when the atria are not positioned in the middle of lead L (left arm) 
and R (right arm) (Boukens et al. 2014). The P wave is followed by PQ (or PR) interval reflecting 
the conduction time from atria to the ventricles (Guyton, Hall 2006, Kaese, Verheule 2012). 
The QRS complex is a result of depolarization of ventricles, which initiates the ventricular 
contraction (Guyton, Hall 2006). The QRS duration varies across the different leads in mice and 
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the last moment of murine ventricular activation was shown to coincide with the end of the QRS 
complex in lead III and aVF. The first phase of repolarization of AP in humans is only transient 
and creates only a small change in the transmembrane potential (Figure 4). Instead, in mice, the 
AP upstroke is followed immediately by a fast downstroke and therefore significant 
repolarization occurs already before the ventricular activation has been completed. 
Consequently, the mouse QRS complex is actually composed of ventricular activation and in 
addition, early repolarization. (Boukens et al. 2013, Boukens et al. 2014.) In the human heart, slow 
ventricular conduction leads to a prolongation of the QRS duration. Instead, recently it was 
reported that when mouse ventricular conduction is slowed, the QRS complex ends before 
ventricular activation is finished. Therefore, the QRS duration might underestimate the total 
activation time of the ventricles. In addition, the total activation time of the left ventricle is shorter 
than in the right ventricle and therefore delayed left ventricular activation, e.g. in the case of left 
bundle branch block, does not necessarily lead to a linear increase in the QRS duration in the 
surface ECG. (Boukens et al. 2013.) 
Due to the different shape of ventricular action potential in mice, the QRS complex is followed 
directly by a J wave, which is temporally situated in the phase of early repolarization (Liu et al. 
2004, Boukens et al. 2013, Speerschneider, Thomsen 2013). J waves may be also present in humans 
in early repolarization, hypothermia and ion channel diseases, such as the Brugada syndrome 
(Antzelevitch 2013).  
 
 
Figure 5. Representative ECG curves of human and mouse. In both human and mouse ECG, one can 
see the P wave (atrial depolarization) and QRS complex (ventricular depolarization). In human ECG, 
the T wave can be distinguished at the end of repolarization. In mouse ECG, there is a J wave at the 
end of the QRS complex which is temporally situated during the early repolarization and furthermore 
there is no clear ST-segment or T wave as the T wave merges with the final part of the QRS complex.  
 
 
The human ventricular activation and repolarization are separated by an isoelectric ST 
segment, during which all ventricular cardiomyocytes are depolarized. This results from the 
plateau phase of the ventricular AP, during which no extracellular current flows and therefore 
no voltage changes are seen in the surface ECG. (Speerschneider, Thomsen 2013, Boukens et al. 
2014.) In the human ECG, the ventricular T wave represents the repolarization of the ventricles 
when the ventricular muscle fibers begin to relax (Guyton, Hall 2006). In mice, there is no evident 
plateau phase and subsequently no clear time point of repolarization but instead a continuous 
repolarization phase after the upstroke phase (Kaese, Verheule 2012). Therefore, there is no clear 
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separate positive T wave, but a negative T wave with a relatively small amplitude that merges 
with the final part of the QRS complex (Kaese, Verheule 2012, Boukens et al. 2014). The end of 
ventricular repolarization coincides with the end of the T wave on ECG (Boukens et al. 2013, 
Speerschneider, Thomsen 2013). The end of the T wave is taken as the point when the ECG 
deflection returns to the isoelectric line and it is most accurately determined with the tangent 
method (Lepeschkin, Surawicz 1952, Boukens et al. 2013, Speerschneider, Thomsen 2013). Despite 
its low amplitude, the end of the T wave in mice is considered to be a good measure of the 
ventricular repolarization end (Speerschneider, Thomsen 2013, Boukens et al. 2014). Since there 
is no ST segment in mice and the mouse J wave seems to be affected in the circumstances where 
there is elevation or depression in the ST segment in humans, the segment between the end of the 
QRS complex and the end of the T wave has been referred to as JT segment in this thesis. 
The QTc, namely QT time corrected for the RR-interval, has been calculated with modified 
Bazzet´s formula specifically modified for mice (Mitchell, Jeron & Koren 1998) in the majority of 
the mouse ECG studies. However, recently it was suggested in a fairly small study (n=6) that this 
formula cannot be recommended for use in anaesthetised mice since repolarization duration is 
independent of HR. Instead, it was claimed that the absolute QT value should be preferred. 
(Speerschneider, Thomsen 2013.)       
 
2.1.5.1 ECG leads 
The standard human ECG consists of 12 leads. Each lead views the heart from a unique angle, i.e. 
has its own angle of orientation, thereby enhancing its sensitivity to a particular region of the 
heart. There are six limb leads: the three standard leads and the three augmented leads, which 
are recorded with two electrodes on the arms and two on the legs. In addition, there are six 
precordial leads recorded with the electrodes placed across the chest. Each lead registers the 
electrical activity of the heart such that an electrical impulse towards the lead is seen as a positive 
reflection in the ECG and an impulse directed away from the lead is seen as a negative reflection. 
(Heikkilä, Mäkijärvi 2003, Thaler 2010.) 
The limb leads view the heart in a frontal plane and the angle of orientation for each lead is 
determined by a line from the negative electrode to the positive electrode. The six limb leads are 
defined as shown in Figure 6. For example, the lead II, which is used in this thesis to record the 
mouse ECG, is created by making the legs positive and the right arm negative and its angle of 
orientation is 60°. It is noteworthy that the amplitude of the P wave is usually most positive in 
the lead II. The angle of orientation for other standard limb leads I and III are 0 and 120°, 
respectively, and the axes of the standard limb leads form a triangle called Einthoven´s triangle.  
Leads II, III and aVF are called the inferior leads since they view the inferior surface of the heart 
most effectively. Leads I and aVL are called the left lateral or apical leads since they have the best 
view of the left lateral and apical wall of the heart and aVR depicts better the right side of the 
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The six precordial leads, or chest leads, are arranged across the chest in a horizontal plane and 
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Figure 6. The six limb leads of the ECG. Three standard limb leads I, II and III form an imaginary 
triangle, called Einthoven´s triangle. In addition there are three augmented leads. The angles of 
orientation for leads I, II and III are 0°, 60° and 120°, respectively. The angles for orientation for 
aVF, aVL and aVR are 90°, -30° and -150°, respectively. (Courtesy of Wikipedia.org, used under 
license.) 
2.2 CARDIOVASCULAR DISEASES 
Cardiovascular diseases (CVD) are the leading cause of death in the world. In 2012, these diseases 
were responsible for the deaths of 17.5 million people, of these 7.4 million were caused by 
ischemic heart disease (IHD) and 6.7 million by stroke. In addition to IHD and stroke, CVDs 
include hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmias, 
congenital heart disease, endocarditis, aortic aneurysms, and peripheral artery disease. (Lozano 
et al. 2012, Nowbar et al. 2014, GBD 2013 Mortality and Causes of Death Collaborators 2015.) 
The main risk factors for CVDs include high LDL-cholesterol concentrations, smoking, 
hypertension, age and diabetes. In addition, a low HDL cholesterol level, high triglyceride levels, 
obesity, physical inactivity, inherited factors, psychological factors and an unhealthy diet play a 
role in the disease development. Many important cardiovascular risk factors are modifiable by 
lifestyle change, drug treatment and the prevention of hypertension, hypercholesterolemia and 
diabetes. (Sleight 2003.) 
This thesis focuses mainly on the animal models of AMI, which is usually caused by an 
atherosclerotic plaque, and LVH, which in humans is often caused by hypertension. 
2.2.1 Atherosclerosis 
Atherosclerosis is the major precursor for IHD in humans. Atherosclerotic lesions start to develop 
when an endothelial dysfunction is triggered by high levels of low-density lipoprotein (LDL) or 
by hypertension. LDL migrates into the intima layer of the vessel wall and becomes oxidized by 
enzymes and reactive oxygen species. The oxidized LDL accumulates and activates endothelial 
cells to produce proinflammatory molecules. For example, monocytes infiltrate into the intima, 
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take up oxidized LDL and form so-called foam cells. This leads to smooth muscle cell migration 
to the intima, where these cells proliferate and synthesize extracellular matrix proteins, increasing 
the size of the fibrous plaques thus narrowing the lumen of the blood vessel. A lipid-rich necrotic 
core is produced as a consequence of the apoptosis and necrosis of foam cells and smooth muscle 
cells leading to the release of oxidized and insoluble lipids into the extracellular space. (Glass, 
Witztum 2001, Libby 2012, Lusis 2000.) 
Advanced plaques have a fibrous cap, foam cells, a large necrotic core, cholesterol crystals, an 
extracellular matrix, calcification, neovascularization and susceptibility to hemorrhage. 
Vulnerable plaques have a thin cap and they are prone to rupture, triggering the formation of a 
thrombus. In fact, acute coronary syndromes are often caused by coronary thrombosis created by 
a ruptured plaque. Instead, cardiac ischemic attacks which become manifested with symptoms 
e.g. chest pain during exercise, are caused by the stenosis of a coronary artery. (Glass, Witztum 
2001, Libby 2012, Lusis 2000.) 
2.2.2 Coronary artery disease and myocardial infarction 
IHD or coronary artery disease (CAD) itself is the most common cause of death in Europe and it 
accounts for 1.8 million deaths each year. About 22% of women and 20% of men die from the 
disease. However, the death rates from CAD have been falling consistently in most European 
countries, including Finland, within the past 30 years. (Nichols et al. 2012.) 
The acute obstruction or occlusion of coronary artery causes acute coronary syndromes (ACS), 
which include unstable angina pectoris, myocardial infarction (MI) without ST-elevation (STE) 
or MI with STE (STEMI). The most common and the most fatal acute manifestation of ACS is 
caused by a ruptured atherosclerotic plaque which forms an occlusive blood clot in an epicardial 
coronary artery provoking an acute reduction of blood flow. This often causes complete or almost 
complete occlusion of the coronary artery lumen, leading to acute transmural ischemia of the 
myocardium, and finally to myocardial necrosis, if reperfusion does not occur rapidly. Acute 
transmural ischemia is usually reflected as STE in the ECG in the leads facing the ischemic area 
and ST-segment depression in the leads facing the anatomically opposite myocardial segments 
(reciprocal changes). Sometimes, due to the presence of flow via collateral circulation, total 
occlusion of a coronary artery does not lead to transmural ischemia. (Heikkilä et al. 2008, 
Birnbaum et al. 2014.) 
Coronary artery occlusion may also result from an embolus or a spasm. In addition to acute 
reduction of blood flow created by an occluded coronary artery, myocardial ischemia may 
develop also due to increased oxygen demand which cannot be accommodated by the current 
blood flow. This may happen due to secondary reasons, like tachyarrhythmia, severe anemia, 
hypertensive crisis or critical aortic valve stenosis associated with CAD or other causes limiting 
the ability of the heart to increase coronary flow. (Heikkilä et al. 2008, Birnbaum et al. 2014.) 
When myocardial ischemia is initiated after the coronary artery is occluded, histological cell 
death takes only 20 minutes to develop. Complete myocardial cell necrosis takes at least 2-4 h 
and after several hours, myocardial necrosis can be identified also in a macroscopic post-mortem 
examination. The entire process leading to an infarction scar takes at least 5-6 weeks to develop. 
(Thygesen et al. 2012.) After MI, the LV undergoes a series of events referred to as remodeling, 
which involve inflammatory, fibrotic and neovascularization responses. The process leads to 
replacement of damaged myocardium by fibrotic tissue leading to contractile dysfunction and 
eventually heart failure (HF). (Virag, Murry 2003, Tiyyagura 2006, Zamilpa et al. 2014.) 
The current treatment strategies for CAD include medication and lifestyle changes. The 
backbone of pharmacological therapy includes lipid-lowering agents (statins), blood pressure 
lowering primarily with angiotensin-converting enzyme inhibitors, acetylsalicylic acid, beta-
blockers and nitrates. The lifestyle changes involve promoting exercise, weight loss, healthy diet 
and cessation of smoking. For more advanced disease invasive methods, i.e. balloon angioplasty 
with stenting or coronary by-pass surgery, are also needed. (Heikkilä et al. 2008, Sleight 2003, 
Augoustides, Ramakrishna 2009, Fajadet, Chieffo 2012.) 
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2.2.2.1 ECG changes in acute myocardial infarction 
The ECG is the most useful diagnostic tool for the initial evaluation and guidance of therapy in 
patients with chest pain. Patients with STE and typical symptoms are usually assigned for 
immediate revascularization therapy, preferentially coronary angioplasty. ECG is the standard 
way of identifying the presence, location and extent of the acute myocardial ischemia and the 
severity of the injury. Acute transmural ischemia may cause changes in the QRS complex, the ST-
segment, and the T-wave morphology in the leads covering the effected area. (Thygesen et al. 
2012, Birnbaum et al. 2014.) The ischemic injury progresses from minor ischemia with changes in 
the T wave to injury evoking changes in the ST segment and finally necrosis, when changes in 
the QRS complex occur (Figure 7a). Since there is no electrical activity in the necrotic area and the 
electrical forces are directed away from the infarcted area, a negative Q wave is recorded in the 
leads overlying the infarct and therefore also the R wave becomes lower. If a large necrotic area 
develops, the R wave might disappear and the QRS complex is seen as a QS wave usually 5-12 
hours after coronary artery occlusion. (Figure 7b.) (Heikkilä, Mäkijärvi 2003, Thaler 2010.) 
An ST segment change is a very early phenomenon in ischemia and it either develops in the Q 
wave or the ST segment disappears. The ST elevation can be massive during the first hours but it 
decreases quickly if the infarction evolves and an electrically silent necrotic area is produced 
which is seen as Q waves. The diastolic and systolic dysfunction are seen with echocardiography 
already before the ST/T changes in ECG and the cardiac dysfunction in the ischemic area is often 
worse in the initial phases of MI. The infarct injury develops within several hours or even days 
to its final size and therefore the ECG changes may continue to evolve for several days. (Heikkilä, 
Mäkijärvi 2003.) In an acute transmural myocardial infarction, the QT time is initially shortened 
in the leads with STE and later, 24-48h h after the onset of infarction, the QT is prolonged. The 
prolongation of the QT time is caused by the delay of the repolarization in the ischemic area. 
(Rossello et al. 2014.) Ischemic injury causes weakening, slowdown and shortening of the AP of 
the ischemic cells (Heikkilä, Mäkijärvi 2003, Rossello et al. 2014). In patients with STEMI the QRS 
is widened, which is though to be caused by delayed electrical activation in the ischemic area 
(Rossello et al. 2014).  
The ST segment change attenuates within one week. If the occlusion of a coronary artery is 
treated with coronary angioplasty, which is the preferred therapy for STEMI, the ST elevation 
normalizes within few hours and the T wave changes usually return to normal within weeks. 
After one month, it is usual that the size of the Q wave becomes reduced and especially in smaller 
infarctions, it might even disappear. (Figure 7b.)  
Non-pathological small septal Q waves can exist in leads I, aVL, aVF and V4-V6 and they are 
< 0.03 sec and < 25 % of the R wave amplitude. The pathological Q waves seen in AMI are wider 
and deeper and they are usually > 0.03 seconds and > 0.1 mV deep. (Thygesen et al. 2012.) 
Acute transmural ischemia after LAD occlusion induces STE usually in the precordial leads, 
mainly in the leads V2-V4. However with a long LAD wrapping around the apex, also inferior 
wall ischemia seen in leads II, III, aVF may be present. The number of leads with STE often 
correlates with the size of the ischemic area, but there are exceptions to this rule. The ECG leads 
detect the global electrical activation of the heart toward and away from the electrode. Therefore, 
simultaneous ischemia in opposing segments of the heart may lead to a cancellation of the STE 
in the leads facing those particular segments. (Birnbaum et al. 2014.)   
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Figure 7. The areas of infarction, ischemic injury and healthy myocardium display different ECGs (a). 
In the early phases of infarction, the STE in the injured area increases in conjunction with the injured 
myocardium.  The STE resolves if the injured area is able to recover after the coronary artery reflow. 
These changes happen very quickly, within tens of seconds. The time course of the progressive ECG 
changes after occlusion of the coronary artery (b). After an hour, STE is seen as a marker of ischemic 
injury. After one day, the Q wave has developed representing necrosis. In addition, the R wave has 
disappeared and therefore the QS wave is seen. STE is still visible indicating that reperfusion has not 
occurred and the artery is still occluded. After one week, the STE has been repaired and the T wave 
is negative indicating that the occlusion has been resolved. After one month, the Q wave has usually 
decreased. Now the T wave has become inverted back to positive, which is a beneficial prognostic 
sign. Modified from Heikkilä (Heikkilä, Mäkijärvi 2003). 
 
 
2.2.2.2 Mouse model of acute myocardial infarction 
Coronary artery ligation in mice has been widely used as a method to induce myocardial 
infarction with either permanent occlusion of the LAD or if one wishes to study ischemia-
reperfusion, then the ligation needs to be loosened after a certain time (Michael et al. 1995, Preda, 
Burlacu 2010). The ligation is usually done through thoracotomy under anesthesia, requires 
intubation and artificial ventilation and is rather time consuming. Recently, the traditional 
method has been modified by Gao et al. such that the heart is manually exposed through a chest 
incision and AMI is induced with LAD ligation. The procedure is quick, taking about a minute 
and therefore there is no need for intubation. In addition, perioperative mortality, the rate of 
arrhythmias and inflammation are less extensive with this new method. Furthermore, the overall 
survival rate is higher compared to the traditional method. (Gao et al. 2010.) Therefore this new 
method was set-up also in our laboratory and was used in this thesis project (study III). 
ECG changes in AMI have not been widely studied in mice, but there are a few reports 
describing ECG findings after acute total occlusion of the LAD. In CD2F1 mice, LAD occlusion 
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for 30 min evoked R wave enlargement (corresponding to the J wave rise described in this thesis), 
ST segment elevation and the development of Q waves 30 min after AMI (Wehrens, Kirchhoff & 
Doevendans 2000). In FVB mice, the early ECG manifestations after LAD ligation included 
diminished R wave amplitude, marked ST segment elevation and the development of a 
significant Q wave. Four and 14 days after AMI, a QS complex without any R wave was seen. No 
differences were detected in the PQ interval, QRS complex width, QT and QTc intervals between 
the sham operated and AMI mice. No sustained arrhythmias were observed but the arrhythmia 
vulnerability was markedly increased after AMI. The ECG changes associated with the sham 
operation were described as transient repolarization abnormalities perioperatively characterized 
by ST segment depression and T wave inversion, with no echocardiographic alterations. 
(Gehrmann et al. 2001.) Ten minutes after LAD ligation in C57Bl/6J mice, there was a prolongation 
of the QRS interval and a JT segment with a positive large T wave was seen without clear JT 
segment elevation (Speerschneider, Thomsen 2013) and it has been interpreted by others that 
AMI in mice is reflected by an S amplitude reduction and not an ST elevation (Boukens et al. 
2014). 
After the LM ligation in male mice of the Rap strain, there was an immediate progressive STE 
and prolongation of the QTc segment; STE increased by 14-fold and the QTc doubled. In their 
hands, the infarct severity progressed from a subepicardial infarct to a transmural infarct 
affecting about 33 % of the LV at about 24 h after ischemia, after which the infarct size did not 
increase. In the ischemia-reperfusion studies, it was noticed that ischemia lasting 1 h induced 
irreversible ECG changes and 24 hours’ ischemia provoked a severe injury which was associated 
with pathological Q waves, inverted T waves and microvoltage abnormalities, which were not 
reversed by reperfusion. (Preda, Burlacu 2010.) 
2.2.3 Left ventricular hypertrophy  
Left ventricular hypertrophy (LVH) is a strong and independent risk factor for premature 
cardiovascular morbidity and mortality. LVH has a poor prognosis and is associated with nearly 
all forms of heart failure. (Katholi, Couri 2011, McMullen, Jennings 2007, Schillaci, Battista & 
Pucci 2012.) 
Ventricular hypertrophy refers to the increased LV mass due to the greater thickness of the 
ventricular wall and/or LV dilatation. LVH can be developed in a secondary manner to 
cardiovascular diseases, which cause a pressure or volume overload on the ventricle or due to a 
primary disease, such as hypertrophic cardiomyopathy. The most common reason for LVH is 
hypertension but there are also other causes e.g. aortic stenosis and mitral valve disease. 
Hypertrophy can be concentric, when the walls are thickened towards the centre of the ventricle, 
thereby decreasing its internal diameter. In eccentric hypertrophy, the ventricular volume and 
the outer border of the ventricle are increased in addition to increased wall dimensions. 
(McMullen, Jennings 2007, Frey, Olson 2003.) 
Cardiac hypertrophy is an adaptation process in response to increased biomechanical stress. 
When the heart is exposed to a sustained increased workload, it increases its mass to normalize 
the pressure in an attempt to maintain blood delivery to the tissues. The hypertrophy is caused 
by enlarged cardiomyocytes, enhanced protein synthesis and formation of new sarcomeres, 
which occur in response to physical stimuli or pathological stress. (Frey, Olson 2003, Heineke, 
Molkentin 2006.) 
LVH can be divided into physiological and pathological hypertrophy. Physiological 
hypertrophy happens in response to chronic exercise training and in women during pregnancy 
and it is associated with normal organization of the cardiac structure and preserved or enhanced 
cardiac function. (McMullen, Jennings 2007.) In pathological hypertrophy, first an adaptive phase 
resembling physiological hypertrophy is seen after which a maladaptive phase occurs. In the 
maladaptive phase, the constant pathological stress can no longer be compensated and therefore 
contractile dysfunction, myocardial fibrosis, changes in metabolism and gene expression occur. 
(Rimbaud et al. 2009, Shahbaz et al. 2010.) 
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The cornerstone of the treatment of LVH associated with hypertensive heart disease is 
effective, long-term antihypertensive therapy. By lowering the blood pressure, the LVH can be 
reversed leading to improved cardiac function and a decreased risk of atrial fibrillation, 
congestive heart failure and cardiovascular mortality. In addition to treatment of hypertension, 
sodium restriction and weight loss are two ways to facilitate the regression of LVH. (Katholi, 
Couri 2011.) 
2.2.3.1 ECG changes in left ventricular hypertrophy 
ECG is the primary technique for detecting LVH in patients with hypertension. Multiple ECG 
criteria have been proposed for LVH. The diagnostic criteria are primarily based on increased R 
wave amplitudes in lateral precordial leads and limb leads, of which the precordial leads are 
more sensitive and limb leads more specific. In LVH, the QRS duration is usually increased. Left 
bundle branch block (LBBB) points strongly to LVH, since up to 90 % of the patients with LBBB 
have LVH. In addition, LVH can be associated with secondary repolarization abnormalities, 
which include the down-sloping ST segment depression and T wave inversion, seen in the leads 
V5-V6 (Figure 8, arrows). These changes are referred to as strain. Repolarization abnormalities 
are the most evident in the leads with tall R waves, i.e. I, aVL, V5 and V6, and are usually 
associated with severe hypertrophy and have been postulated to predict the onset of ventricular 
dilatation. (Heikkilä, Mäkijärvi 2003, Thaler 2010, Schillaci, Battista & Pucci 2012.) 
 
 
Figure 8. An ECG example of severe left ventricular hypertrophy caused by aortic valve stenosis. The 
amplitude of the S wave in V1 lead and R wave in leads V5-V6 is markedly increased. In addition, 
secondary repolarization abnormalities in lateral leads (V5-V6) are seen as ST depression with 
secondary T wave inversion (marked with arrows). Modified from Heikkilä (Heikkilä, Mäkijärvi 2003). 
 
2.2.3.2 Mouse models of left ventricular hypertrophy 
In mice, LVH is most often evoked by the angiotensin II (angII) induced hypertension model or 
with a surgical pressure overload model created by transverse aortic constriction (TAC) (Foldes 
et al. 2001, Rockman et al. 1991). Chemical induction of hypertension and LVH with ang II is easy 
to perform with osmotic minipumps, but the overall influence of the elevated blood pressure due 
to activation of the renin-angiotensin-aldosterone system must be taken into account. The TAC 
model is created by visualizing the aortic arch through thoracotomy and placing a suture around 
the aorta between the brachiocephalic trunk and left arteria carotis communis. The suture is then 
tied around a 25-G needle, which is subsequently removed. This leads to compensatory LVH with 
17 
 
 
increased LV wall thickness and decreased left ventricular end-diastolic diameter (LVEDD) 2 
weeks after the TAC operation.  Subsequently, it can lead to decompensated LVH with increased 
LV wall thickness and LVEDD and decreased ejection fraction (EF) at 4 weeks which further 
escalates towards the 10 week timepoint. The LVH is associated histologically with progressive 
LV fibrosis. (Huusko et al. 2012.)   
The severity of progressive LVH and the following HF can be modulated in the TAC model. 
By using a thicker needle for the aortic constriction, a looser ligation and milder, more slowly 
progressing LVH is generated. Transgenic and knock-out mice represent novel tools with which 
to study the molecular mechanisms behind LVH. 
As far as is known, the surface ECG changes in the compensatory phase of progressive LVH 
in the widely used TAC model have not been previously studied to a large extent. It has been 
demonstrated that 6-8 weeks after TAC when EF was below 40 % indicative of HF, there were 
increases in HR, QRS width and QT interval. In addition, an entirely negative J segment (lead II) 
without any clear separation between the J and T waves was seen. (Speerschneider, Thomsen 
2013.) 16 weeks after TAC, after the LV dilatation and HF, the QRS complex was widened (by 31 
%) and there was increased prevalence of ventricular tachycardia (Boulaksil et al. 2010). In a 
transgenic mouse line with cardiac-specific overexpression of ErbB2, the mice develop massive 
concentric LVH with tripled LV mass and the ECG changes seen in lead II display a shortened 
PR interval, increased QRS complex width and amplitude together with repolarization 
abnormalities (Sysa-Shah et al. 2012).  
2.3 GROWTH OF NEW VESSELS 
In adults, blood vessels grow mainly by two processes, angiogenesis and arteriogenesis, which 
will be discussed in detail below. The induction of vessel growth is a natural endogenous 
response to many physiological and pathological processes. In myocardial ischemia, endogenous 
angiogenesis is induced by hypoxia induced signaling (Li et al. 1996) and arteriogenesis is 
triggered by increased vessel wall shear stress (Scholz, Cai & Schaper 2001); these can be 
considered to be attempts to bypass the occluded coronary arteries and increase blood flow to 
ischemic areas. Therefore, gene therapy with VEGFs could be beneficial by enhancing the natural 
endogenous response.  
During recent years, also the concept of postnatal vasculogenesis has emerged. This term refers 
to the de novo recruitment of bone marrow-derived endothelial progenitor cells (BM-EPCs) and 
circulating EPCs for blood vessel formation in adults. Circulating EPCs may home to sites of 
neovascularization and differentiate into endothelial cells in situ. (Asahara, Kawamoto 2004, 
Eguchi et al. 2007, Kopp et al. 2006.) EPC therapy is currently being evaluated as a novel treatment 
option for therapeutic revascularization and vascular repair in ischemic diseases (Lee, Poh 2014, 
Sukmawati, Tanaka 2015). 
2.3.1 Angiogenesis 
Angiogenesis means the formation of new vessels by sprouting or intussusception from the pre-
existing vessels (Potente, Gerhardt & Carmeliet 2011). Angiogenesis is thought to be the main 
mechanism by which vessel growth is induced in adults and it has an important role in 
physiogical processes like the menstrual cycle and wound healing and in pathological processes, 
such as tumour growth (Risau 1997). The main inducing event for angiogenesis is local tissue 
hypoxia. Low oxygen levels stimulate hypoxia sensitive factors, such as HIF-1α, leading to the 
production and release of angiogenic growth factors, like VEGFs (Marti 2005). 
The process of angiogenesis has multiple steps. Firstly, the initial capillary vessel is dilated 
primarily due to nitric oxide (NO), followed by angiopoietin-2 mediated detachment of the 
pericyte coverage and loosening of the underlying matrix, which allows endothelial cells to 
migrate. The basement membrane surrounding the endothelial cells becomes degraded, followed 
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by the release of pericyte-derived angiogenic factors by the action of matrix metalloproteinases 
(Carmeliet, Jain 2011). VEGF-A induces an increase in vascular permeability and plasma protein 
extravasation, which creates a suitable matrix for the endothelial cell activation and migration, 
resulting in the formation of the ultrastructure for the new angiogenic vessels (Jain 2003). The 
process of endothelial cell proliferation and migration is an interplay between various forms of 
VEGFs, angiopoietins, fibroblast growth factors (FGSs) and their receptors (Conway, Collen & 
Carmeliet 2001). 
The newly formed neovasculature is remodeled to respond to the needs of the host tissue 
depending on whether there are normoxic or hypoxic conditions. Those vessels with insufficient 
blood flow are pruned and undergo apoptosis. (Dor, Porat & Keshet 2001, Sho et al. 2001.) The 
angiogenic vessels that have remained stable long enough for the surrounding pericytes and 
mural cells to proliferate or differentiate in order to form the vessel wall, are stabilized and a new 
basement membrane begins to form around the maturing vessel (Abtahian et al. 2003). It has been 
also demonstrated that even a pericyte covered angiogenic neovessel might be removed 
(Rissanen et al. 2005). 
Angiogenesis is also a necessary process for tumor growth. Without sufficient vascularization, 
tumors are unable to grow beyond a diameter of 1 mm and undergo necrosis. Therefore, anti-
angiogenic therapies are used in the treatment of many different cancers. (Carmeliet, Jain 2011.) 
2.3.2 Arteriogenesis 
Arteriogenesis means the growth and remodeling of pre-existing collateral anastomoses 
associated with the coronary arteries when one is considering the heart (Meier et al. 2013, Seiler 
et al. 2013, Heil, Schaper 2004, Heil et al. 2006). The most important trigger for collateral growth 
is increased tangential fluid shear stress at the endothelial surface which is initiated when a 
functional coronary artery becomes critically constricted or totally occluded. This causes a 
pressure gradient between the area proximal to the coronary stenosis and the downstream low-
pressure post-stenotic area leading to redirection of the blood flow through the pre-existing 
collateral network in an attempt to bypass the occlusion. The increase in collateral blood flow 
stretches the vessel and causes shear stress against the vessel wall, leading to release of NO, which 
further induces the dilatation of collateral vessels and distal arterioles. In addition, endothelial 
activation is induced leading to expression of chemoattractants, like monocyte chemoattractant 
protein-1 (MCP-1), and activating cytokines. (Meier et al. 2013, Heil, Schaper 2004.) The 
monocytes which have migrated to the site play a key role in orchestrating collateral remodeling, 
including attraction of EPCs by releasing growth factors (Meier et al. 2013). The growth process 
in arteriogenesis depends on the proliferation of endothelial cells, smooth muscle cells and 
adventitial fibroblasts and it occurs about one day after the invasion of monocytes (Heil, Schaper 
2004). The dominant growth factors during the cellular proliferation are fibroblast growth factors 
(FGFs) released mainly by the monocytes and indeed, gene therapy with FGF has resulted in 
increased arteriogenesis (Fernandez et al. 2000, Rissanen et al. 2003a). 
Collateral growth is continued until the pressure and shear stress affecting the vessel wall 
return to normal once the vessel wall diameter has increased by about 20-fold (Heil, Schaper 
2004). Properly developed collaterals have been shown to been able to compensate for even the 
lack of one of the main coronary artery and thus their presence has an effect on the clinical 
symptoms (Seiler et al. 2013, Rockstroh, Brown 2002). 
2.4 VASCULAR ENDOTHELIAL GROWTH FACTORS AND THEIR RECEPTORS 
The family of VEGFs regulates all types of vascular growth in physiological and pathological 
conditions. There are several members in the VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D 
and placental growth factor (PlGF). In addition to these mammalian members, viral VEGF 
homologues (called collectively VEGF-E) and snake venom VEGFs (called VEGF-F and Vammin) 
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have been detected. VEGFs are dimeric glycoproteins which bind with different affinities to three 
tyrosine kinase receptors, VEGF-R1 (Flt1), VEGF-R2 (Flk-1/KDR), and VEGF-R3 (Flt-4) and two 
co-receptors, Nrp-1 and Nrp-2, which initiates the formation of receptor homo- and heterodimers. 
In addition, naturally occurring soluble isoforms of VEGF-R1, VEGF-R2, VEGF-R3, Nrp-1 and 
Nrp-2 regulate the efficiency of VEGFs. (Ferrara 2004, Smith et al. 2015.) Figure 9 summarizes the 
binding of VEGFs to their receptors. 
 
 
 
Figure 9. VEGFs and their receptors. VEGF-A binds to VEFG-R1, VEGF–R2, Nrp-1 and Nrp-2. VEGF-B 
binds to VEGF-R1 and Nrp-1. PlGF binds also to VEGF-R1 and Nrp-1 and in addition to Nrp-2. VEGF-C 
and VEGF-D bind to VEGF-R2, VEGF-R3 and both Nrps. VEGF-E, VEGF-F and Vammin bind to VEGF-
R2, in addition, VEGF-E binds to Nrp-1. Modified from Vuorio (Vuorio, Jauhiainen & Yla-Herttuala 
2012).  
 
 
VEGF-Rs possess an extracellular ligand-binding domain composed of immunoglobulin-like 
loops, a transmembrane domain which enables the dimerization of the receptors, a 
juxtamembrane domain, an intracellular tyrosine kinase domain and a C-terminal tail. The 
receptors are activated by binding of VEGFs to the extracellular domain, which leads to homo- 
or heterodimerization and subsequent phosphorylation of the tyrosine residues. This initiates 
complex downstream signal transduction cascades mediating the various biological effects of the 
VEGFs. (Smith et al. 2015, Koch et al. 2011, Koch, Claesson-Welsh 2012, Yla-Herttuala et al. 2007.)  
VEGF-A binds to VEGF-R1 and VEGF–R2. VEGF-R1 functions as a negative regulator of 
angiogenesis during embryogenesis. Instead, in adults, VEGF-R1 functions as a positive regulator 
of angiogenesis, since it activates endothelial cell proliferation, promotes tumor growth, 
metastasis and inflammation (Shibuya 2006). VEGF-R2 mediates the proliferative, chemotactic 
and angiogenic responses by inducing several intracellular signaling cascades, with the main 
ones being mediated via  Phosphoinositide 3-kinase (PI3K), AKT, endothelial nitric oxide 
synthase (eNOS), phospholipase C gamma (PLCg), PKC (protein kinase C), extracellular-signal-
regulated kinase (ERK), p38 mitogen-activated protein kinase (p38MAPK) and proto-oncogene 
tyrosine-protein kinase Src. PlGF and VEGF-B are specific ligands for VEGF-R1. VEGF-E and 
VEGF-F are unique in their ability to bind to and activate specifically VEGF-R2. VEGF-C and 
VEGF-D are produced as large precursor forms which undergo proteolytic cleavage by plasmin 
and other proteases to release the C- and N-terminal extensions. After proteolytic cleavage, their 
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binding affinities, especially their affinity for the VEGF-R2, are increased several-fold. The 
responses mediated via VEGF-R3 are related to lymphangiogenic signaling. Nrp-1 and Nrp-2 are 
co-receptors for VEGF-R1, VEGF-R2 and VEGFR-3 and they act to enhance and amplify the effects 
of the VEGFs. Soluble forms of VEGF-R1, VEGF-R2 and VEGF-R3 participate in the regulation of 
VEGFs since they function as competitive inhibitors of the binding of VEGFs to the cell surface-
bound receptors. (Smith et al. 2015, Vuorio, Jauhiainen & Yla-Herttuala 2012, Koch, Claesson-
Welsh 2012.) 
The more detailed roles of the VEGFs used in this thesis, namely VEGF-A, VEGF-B and VEGF-
E will be discussed in the following sections. 
2.4.1 VEGF-A 
VEGF-A was the first identified member of the VEGF family; it is the master regulator of 
angiogenesis and vascular permeability. It is the most important growth factor affecting the 
vasculature and its growth. (Ferrara 2004, Smith et al. 2015, Yla-Herttuala et al. 2007.) VEGF-A is 
indispensable for vascular development, since deletion of even a single allele of the gene results 
in embryonic lethality due to immature blood vessel formation (Carmeliet et al. 1996, Ferrara et 
al. 1996).  In adults, VEGF-A is expressed in all vascularized tissues, especially in the proximity 
of fenestrated vessels, such as those located in kidneys and endocrine tissues. It is also expressed 
in tissues with sinusoidal vessels, like liver and spleen as well as in large vessels, skeletal muscle 
and myocardium. (Maharaj et al. 2006.) Alternative splicing of VEGF-A mRNA leads to a number 
of different isoforms, which are named according to their amino-acid length. These isoforms 
differ in their molecular weight, heparin-sulfate (HS) binding properties and their affinity for the 
receptors. VEGF-A165 is the predominant form which binds to Nrp-1 and HSs and therefore is 
trapped on the cell surface or in the extracellular matrix. Instead, the shortest form, VEGF-A121, is 
freely soluble and secreted, and the largest forms, VEGF-A189 and VEGF-A206 are tightly bound to 
HS and exist mainly in the extracellular matrix. (Houck et al. 1992.)  
VEGF-A seems to have a crucial role in maintaining the vascular homeostasis, since lack of 
sufficient levels of VEGF-A results in endothelial dysfunction, hypertension, ischemia and blood 
clotting (Yla-Herttuala et al. 2007, Lee et al. 2007, Maynard et al. 2003, Ratner 2004). Higher levels 
of VEGF-A induce physiological vascular growth, but very high concentrations of VEGF-A 
promote aberrant vascular growth with the formation of blood lacunae and significant tissue 
edema (Rissanen et al. 2005, Yla-Herttuala et al. 2007, Korpisalo et al. 2011). 
The expression of VEGF-A is regulated by hypoxia via upregulation of hypoxia inducible 
factor-1 (HIF-1). The main angiogenic signaling and induction of vascular permeability is 
mediated via VEGF-R2. Because of its high angiogenic potency, VEGF-A has been the prime 
candidate for therapeutic applications in vivo, although the edema formation which results from 
the increased vascular permeability makes VEGF-A a less useful growth factor if one strives to 
evoke therapeutic angiogenesis. VEGF-A is up-regulated during processes involving 
physiological angiogenesis, such as corpus luteum development, exercise-induced angiogenesis 
in skeletal muscle and in tissue regeneration after injury or ischemia. (Ferrara 2004, Yla-Herttuala 
et al. 2007, Rissanen et al. 2002.) VEGF-A acts also as a strong chemotactic cytokine, since it 
recruits monocyte/macrophages via VEGF-R1 signalling, leading to inflammation in vivo (Zheng 
et al. 2006). 
The angiogenic effects of VEGF-A are also needed to allow tumours to grow and vice versa: 
inhibition of VEGF-A with VEGF blockers like bevacizumab (Avastin), a recombinant humanized 
monoclonal antibody that targets VEGF-A, is used to inhibit or delay tumour growth in many 
different cancer types (Carmeliet, Jain 2011, Ferrara, Hillan & Novotny 2005, Mukherji 2010). In 
addition to cancer, the anti-angiogenic approach has been efficient in the therapy of age-related 
macular degeneration (Carmeliet, Jain 2011). 
VEGF-A has been primarily thought to be a pro-angiogenic factor. However,  fairly recently 
an anti-angiogenic splice variant, VEGF-A165b, was discovered (Bates et al. 2002). Alternative 
splicing of the exon 8 generates specific anti-angiogenic forms of VEGF, that are widely expressed 
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in normal human tissues but their expression is downregulated in certain pathological situations 
associated with abnormal angiogenesis, like cancer (Harper, Bates 2008, Qiu et al. 2009). 
Understanding the roles of these anti-angiogenic splice variants will surely revise our current 
knowledge of VEGF biology (Qiu et al. 2009) and might explain the somewhat disappointing 
efficacy of anti-VEGF therapies on the overall survival of patients with different forms of cancers 
(Guyot, Pages 2015). 
2.4.2 VEGF-B 
VEGF-B is expressed in many tissues but the highest levels are seen in metabolically active 
tissues, that is in myocardium, skeletal muscle and brown adipose tissue. There are two isoforms 
of VEGF-B; heparin-binding VEGF-B167 and freely soluble VEGF-B186. (Olofsson et al. 1996b, 
Olofsson et al. 1996a.) Both isoforms bind to VEGF-R1 and Nrp-1 and can form heterodimers with 
VEGF-A, which can then bind to VEGF-R2 (Bry et al. 2014). 
Compared with the other VEGF family members, VEGF-B has been the least studied and its 
role has remained somewhat enigmatic. It appears to have no obvious function under normal 
conditions;  it appears to function as a multifunctional safeguarding molecule that can act as a 
survival factor rescuing cells from death and also as a growth-inhibiting factor to inhibit 
overgrowth. (Li et al. 2012 .) Two VEGF-B knockout mouse models exist, both of which are largely 
healthy and fertile. In the VEGF-B-/- mice created by Bellomo, the mice had smaller hearts and 
displayed an impaired recovery after myocardial ischemia with vascular dysfunction in the heart 
(Bellomo et al. 2000). The other VEGF-B-/- mouse model exhibited an atrial conduction defect with 
a prolonged PQ interval, without other changes in the heart or other tissues (Aase et al. 2001). 
When these mouse lines were exposed to a high-fat diet, they did not show any metabolic changes 
or cardiac phenotype change indicating that VEGF-B may be dispensable under non-stressed 
conditions (Dijkstra et al. 2014). 
The angiogenic potential of VEGF-B seems to be limited to the myocardium and the beneficial 
cardiac effects also appear to be mediated by metabolic effects. Intramyocardial VEGF-B186 gene 
therapy in a pig infarction model induced therapeutic angiogenesis and arteriogenesis together 
with antiapoptotic and metabolic effects (Lähteenvuo et al. 2009). In a progressive LVH mouse 
model, VEGF-B186 gene therapy rescued the function of the failing heart due to enhanced 
angiogenesis, inhibition of apoptosis, promotion of cardiomyocyte proliferation and the reversal 
of fetal gene expression, a well-known phenomenon in heart failure (Huusko et al. 2012). VEGF-
B167A gene therapy improved diastolic function in AngII-induced LVH in rats (Serpi et al. 2011). 
Cardiac specific overexpression of VEGF-B expanded the coronary arterial tree and protected 
against ischemia and HF (Kivela et al. 2014). Instead, it seems that VEGF-B has a minimal 
angiogenic potential in skeletal muscles (Rissanen et al. 2003b). 
The angiogenic potential of VEGF-B seems to be also related to the isoform used, since as 
described, the freely soluble form VEGF-B186 was effective in diseased mouse heart in progressive 
LVH model (Huusko et al. 2012), in intact pig heart and in pig AMI model (Lähteenvuo et al. 
2009). Instead, Pepe et al. have previously revealed that AAV9-VEGF-B167 treatment could delay 
the progression of tachypacing-induced LVH towards HF via a non-angiogenic cardioprotective 
effect by inhibiting apoptosis (Pepe et al. 2010). 
Recently, it has been shown that VEGF-B plasma levels are increased after AMI in human 
patients and this increase correlates with the preservation of cardiac function. Instead, low 
circulating levels of VEGF-B are associated with a high risk of developing adverse LV remodeling. 
(Devaux et al. 2012.) In addition, VEGF-B expression was significantly decreased in both ischemic 
heart disease and dilated cardiomyopathy compared to non-failing hearts. These findings suggest 
that increased levels of VEGF-B might be beneficial in cardiac patients. (Kivela et al. 2014.) 
In addition, VEGF-B has been shown to exert neuroprotective effects (Poesen et al. 2008, 
Guaiquil et al. 2014), to promote cancer metastasis and serve as a marker of poor prognosis for 
cancer patients (Yang et al. 2015). 
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2.4.3 VEGF-E 
VEGF-E is an Orf-virus derived protein, which is structurally and functionally related to 
mammalian VEGFs. Three VEGF-E family members have been identified, VEGF-ENZ-7, VEGF-ENZ-
2 and VEGF-ED1701, which are named after the Orf-virus strains from which they were isolated. 
VEGF-ENZ-7 specifically binds to and activates only VEGF-R2, which is a unique feature of this 
growth factor. It has very strong affinity to VEGF-R2, although its amino acid homology with 
VEGF-A is low. VEGF- ENZ-7 does not have a typical heparin-binding domain and it does not bind 
Nrps. (Lyttle et al. 1994, Ogawa et al. 1998, Shibuya 2011.) Instead, VEGF-ENZ-2 has been shown to 
bind also to Nrp-1, in addition to VEGF-R1, while having mitogenic activity on endothelial cells 
and being able to induce vascular permeability (Wise et al. 1999). VEGF-ENZ-7 promotes 
endothelial cell growth and survival at similar levels than VEGF-A165 and is less potent in 
inducing vascular permeability. Soluble VEGF-R1, which is a potent inhibitor of VEGF-A, does 
not suppress the activity of VEGF-E. (Lyttle et al. 1994, Ogawa et al. 1998, Shibuya 2011, Meyer et 
al. 1999.) 
In a transgenic mouse model with overexpression of VEGF-ENZ-7 under a Keratin-14 promoter, 
which directs the expression mainly to the skin, there was an intense angiogenic response without 
edematous lesions and hemorrhagic spots on the ear and other dermal tissues (Kiba et al. 2003), 
which were seen in VEGF-A transgenic mice (Larcher et al. 1998).  
VEGF-E chimeras consisting of VEGF-ENZ-7 and human PlGF derived amino acids at amino 
and carboxy terminal ends represent humanized forms of VEGF-E; these have shown reduced 
antigenicity compared to native viral VEGF-ENZ-7 (Zheng et al. 2006, Kiba et al. 2003). In VEGF-
ENZ-7/PlGF- transgenic mice, in which the transgene was driven by a Keratin-14 promoter, a strong 
angiogenic response was observed in the skin with less vascular leakage and inflammation 
compared to VEGF-A165 transgenic mice (Zheng et al. 2006). In a rat model of hindlimb ischemia, 
intramuscular administration of a VEGF-ENZ-7/PlGF chimera plasmid stimulated angiogenesis to 
a similar level than human VEGF-A but with less infiltration of macrophages (Inoue et al. 2007). 
VEGF-E chimeras are thought to be less immunogenic than VEGF-A due to VEGF-R2 specific 
binding, enabling induction of angiogenesis without high vascular permeability and 
inflammation (Zheng et al. 2006). 
Due to the significant induction of angiogenesis in vivo with only minor side effects, VEGF-E 
family members should be further studied as potential angiogenic factors to be used in pro-
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expressed on lymphatic endothelial cells and stimulate lymphangiogenesis.  In addition, they 
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is an endothelial cell mitogen when acting via VEGF-R2 and it acts as angiogenic factor in skeletal 
muscle and heart (Rissanen et al. 2003b, Rutanen et al. 2004). 
PlGF is expressed in four different isoforms, PlGF 1-4, of which only PlGF-2 is expressed in 
mice (Cao et al. 1997, Fischer et al. 2008, Maglione et al. 1991, Maglione et al. 1993, Yang et al. 
2003). PlGFs bind to VEGF-R1 and PlGF-2 has also Nrp-1 binding properties (Migdal et al. 1998, 
Park et al. 1994, Sawano et al. 1996). PlGF deficient mice are healthy and fertile with a normal 
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vasculature, but they have increased vascular permeability and impaired angiogenesis and 
collateral vessel growth in ischemia, inflammation, wound healing and cancer (Carmeliet et al. 
2001). PlGF gene therapy has been proven to induce angiogenesis and collateral growth in 
ischemic heart and limb, probably via up-regulation of VEGF-A (Luttun et al. 2002, Roy et al. 
2005) and it has been shown to form VEGF-R2 -binding heterodimers with VEGF-A (Cao et al. 
1996). 
VEGF-F members, Vammin and VR-1, are snake venom derived proteins which possess 
heparin-binding properties. They are VEGF-R2 specific ligands which have shown strong 
proliferative effects on vascular endothelial cells (Yamazaki et al. 2003, Yamazaki et al. 2005b, 
Yamazaki et al. 2005a). Vammin binds with high affinity to VEGF-R2 and its angiogenic potency 
is comparable to that of VEGF-A165 in vitro (Nieminen et al. 2014). The angiogenic efficacy of 
Vammin has also been demonstrated in vivo in rabbit skeletal muscles where it induced increased 
muscle blood perfusion, capillary size and vascular permeability (Nieminen et al. 2015). 
2.5 GENE THERAPY FOR CARDIOVASCULAR DISEASES 
2.5.1 Principles of gene therapy 
Gene therapy refers to the treatment of diseases by introducing therapeutic genes into somatic 
cells. A gene construct encoding the therapeutic protein is transferred into the somatic target cells 
in a process called transduction such that the targeted cells are stimulated to produce the desired 
therapeutic protein. Gene therapy possesses several advantages over conventional therapies e.g. 
the possibility to use endogenous proteins for treating only the affected tissue. In addition, long-
term therapeutic effects can be achieved by a single application. However, the efficient delivery 
of the gene product to the target cells requires a gene delivery vehicle, a vector. (Yla-Herttuala, 
Alitalo 2003.) 
The vast majority of gene therapy clinical trials have used viral vectors to transfer nucleic acids 
into the target cells. Viruses are nanoscale-sized objects which utilize a very efficient mechanism 
to internalize their own genome into the target cells. This feature is exploited in viral vectors, 
which are genetically modified by removing most of the genes encoding for viral proteins, 
especially those that are potentially pathogenic, and these are substituted with the therapeutic 
nucleic acids. (Giacca, Zacchigna 2012.) 
The efficacy of gene therapy is determined by several factors; how the gene construct is 
delivered to the target tissue, how efficiently the gene construct produces the therapeutic protein, 
what is the duration of the protein expression and what is the biological efficiency of the 
therapeutic protein to mediate the desired therapeutic effect (Giacca, Zacchigna 2012, Kay, 
Glorioso & Naldini 2001, Kootstra, Verma 2003, Korpisalo, Yla-Herttuala 2010). 
Therapeutic genes can be delivered via systemic routes or by local administration. Systemic 
delivery via iv or ia routes leads to the accumulation of the viral particles in the liver and the 
spread of the gene product also to off-target tissues, thereby decreasing the amount of gene drug 
in the desired target tissue. In addition, the large tissue and blood volumes in humans would 
need enormous amounts of gene product and therefore systemic delivery is usually not a possible 
approach. (Karvinen, Yla-Herttuala 2010.) In small animals like mice, the systemic administration 
is feasible for screening the effects of gene products in proof-of-principle studies. However in 
general, local gene delivery is usually more effective and produces less undesired side-effects 
(Yla-Herttuala 2013). 
Cell surface receptors mediate the internalization of the vector and therefore strongly regulate 
the access of the vector into the target cells. In order to achieve efficient gene delivery, the vector 
needs to be chosen to best suit the receptor profile of the target cells.  For example, adenoviruses 
enter the cells using mainly coxsackie-adenovirus receptors (CAR) and integrin receptors; these 
are highly expressed in cardiomyocytes and hepatocytes, whereas in skeletal muscle, the amount 
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of CAR is limited. Instead, adeno-associated viruses (AAVs) have several serotypes, which differ 
in their binding abilities to different tissues due to differences in the composition of the viral 
capsid proteins. It is possible to modulate the transduction efficiency of a particular vector by 
modifying the vector capsid proteins. By incorporating tissue specific gene promoters, transgene 
expression can be limited to the target tissue. (Korpisalo, Yla-Herttuala 2010, Karvinen, Yla-
Herttuala 2010). 
2.5.2 Cardiovascular gene therapy 
Current treatments for cardiovascular diseases, like CAD, are based on disease prevention and 
revascularization of the ischemic myocardium. However, the conventional revascularization 
approaches are not applicable in all patients, e.g. in patients having widespread diffuse disease 
and in elderly patients with many co-morbidities. Therefore, there is an obvious need to develop 
minimally invasive revascularization methods for patients with severe coronary heart disease 
who cannot benefit from the conventional treatment options. Therapeutic angiogenesis i.e. 
stimulation of new blood vessels to replace occluded vessels, offers a potential novel way of 
treating CVDs also in these “no-option” patients. (Halonen et al. 2014.) 
Both collateral growth and angiogenesis are natural processes occurring in a human 
myocardium suffering a vessel occlusion (Silvestre, Smadja & Levy 2013). Induction of the 
expression of growth factors, such as VEGFs, is a response to increased vessel wall shear stress in 
arteriogenesis and to hypoxia in angiogenesis (Silvestre, Smadja & Levy 2013, Yla-Herttuala, 
Alitalo 2003). Naturally occurring angiogenesis and arteriogenesis are impaired by old age, high 
cholesterol levels, diabetes and endothelial dysfunction, which are often present in the very 
patients for whom the conventional revascularization techniques cannot be applied (Silvestre, 
Smadja & Levy 2013, Markkanen et al. 2005). However, by introducing an exogenous angiogenic 
cytokine or growth factor, these limitations can be overcome (Rivard et al. 1999). This supports 
the usefulness of gene therapy as a beneficial way of inducing both arteriogenesis and 
angiogenesis. In particular, collateral vessel growth occurs proximal to the coronary occlusion 
site in the normoxic myocardium. The induction of arteriogenesis can be beneficial in severe, 
multivessel CAD as a preventive treatment and also after acute AMI for improving the function 
of the conducting vessels (Yla-Herttuala, Martin 2000). Angiogenesis increases tissue perfusion 
locally in ischemic areas. In acute AMI, a rapid and efficient overexpression of growth factors 
inducing angiogenesis in the peri-infarct zone would be an excellent way of increasing perfusion 
in the ischemic area. It could also help the so-called hibernating myocardium, which is the still-
viable but quiescent tissue around the infarcted area, to receive sufficient blood flow. (Markkanen 
et al. 2005.) As angiogenesis increases the vessel area and thereby local tissue perfusion, it also 
lowers the local capillary resistance. This results in increased flow in the proximal arteries with 
the same pressure and thus also arteriogenesis can be induced secondarily to angiogenesis, which 
is essential for compensating the blood flow in the territory of the occluded artery and for 
sustaining cardiac function. (Schaper, Ito 1996.) AMI patients are often subjected to invasive 
treatments and gene transfer could be done either independently or in combination with an 
intravascular revascularization procedure or during bypass surgery (Markkanen et al. 2005). 
The most commonly applied approach in cardiovascular gene therapy trials has been to induce 
vascular growth by locally overexpressing one of the growth factors naturally participating in the 
process (Halonen et al. 2014). Angiogenic gene therapy has evolved into a promising approach 
by stimulating the growth of the whole vascular tree, including large conducting arteries, veins 
and capillary vessels (Korpisalo, Yla-Herttuala 2010) and it has shown good efficacy in pre-
clinical trials (Yla-Herttuala 2013, Rissanen et al. 2005, Lähteenvuo et al. 2009, Rutanen et al. 2004). 
The VEGF family members are major stimulators of vascular growth and are some of the most 
attractive growth factors in future clinical trials (Yla-Herttuala et al. 2007). For example, 
intramyocardial AdV gene transfer of the processed form of VEGF-D using the NOGA system 
has achieved efficient transmural angiogenesis with increased myocardial perfusion in pig heart 
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(Rutanen et al. 2004) and this approach has progressed into a clinical trial (KAT301 for the 
treatment of severe coronary heart disease, https://clinicaltrials.gov/show/NCT01002430). 
One of the most important factors limiting the effectiveness of gene therapy is the 
establishment of clinically relevant methods of gene transfer (Katz et al. 2012). Local gene transfer 
techniques with direct intramyocardial injections have been shown to be clearly more efficient 
than either ia or iv administration (Yla-Herttuala 2013, Rissanen, Yla-Herttuala 2007). When 
treating ischemic disease, an intra-arterially injected gene transfer vector is unlikely to reach areas 
with severily impaired perfusion, and these are the areas with the greatest need for a therapeutic 
intervention. In addition, systemic administration is more likely to result in the spread of the 
injected agent outside the target tissue. Pericardial gene delivery is also unlikely to create efficient 
transmyocardial transduction. Intramyocardial injections are currently the most effective gene 
transfer method; these can be done percutaneously without the need for thoracotomy by using 
intracardiac catheter systems, like the NOGA system. (Katz et al. 2013, Yla-Herttuala et al. 2007.) 
High enough concentrations of growth factors are needed in order to achieve optimal 
biological effects. In intact skeletal muscle, low doses of VEGF induce capillary sprouting without 
causing any metabolic effects, instead, higher VEGF concentrations are needed for inducing 
capillary enlargement, which lead to increased total tissue perfusion and improved aerobic 
energy metabolism (Korpisalo et al. 2011). 
2.5.3 Gene therapy vectors 
The vectors used in gene therapy can be divided into viral vectors and non-viral vectors, based 
on their biological background. Viral vectors can be further divided into integrating and non-
integrating vectors depending on their ability to integrate into the host cell genome. Different 
vector types have different gene transfer efficacies in different tissues and the expression time of 
the gene product varies. (Kay, Glorioso & Naldini 2001, Kootstra, Verma 2003, Korpisalo, Yla-
Herttuala 2010.) 
In the following chapter, the three most commonly used viral vectors in cardiovascular gene 
therapy, and also in this thesis, will be discussed in more detail, mainly in the context of cardiac 
gene therapy. The most important advantages and disadvantages associated with these particular 
vectors are summarized in Table 1. 
Plasmids are the most important non-viral vectors, but their efficiency in in vivo applications 
is far from that achievable with viral vectors and they have not produced beneficial effects in 
clinical trials. Therefore, it has been stated that viral vectors will be the vectors of choice in future 
clinical trials. (Yla-Herttuala, Alitalo 2003, Korpisalo, Yla-Herttuala 2010.)  
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Table 1. The three most commonly used vectors in cardiovascular gene therapy. Modified from 
Rissanen and Ylä-Herttuala (Rissanen, Yla-Herttuala 2007). 
 
 
Vector Advantages Disadvantages 
Adenovirus - High transduction efficiency  
- Relatively high transgene capacity  
- Easy to produce in high titers 
- Transduces quiescent cells  
- Tropism for multiple cells 
 
- Inflammation with high doses 
- Transient transgene expression 
Adeno-associated virus - Long-term gene expression 
- Moderate immune response 
- Transduces quiescent cells 
- High tropism for myocardium 
(AAV-8 and -9) 
- Wildtype does not cause disease 
in humans 
 
- Limited transgene capacity 
- Difficult to produce in large 
quantities 
 
Lentivirus - Long-lasting gene expression  
- Transduces quiescent cells 
- Relatively high transgene capacity  
- Low immune response 
- Random integration 
- Low transduction efficiency  
- Limited tropism  
- Difficult to produce in large 
quantities 
 
 
 
2.5.3.1 Adenovirus vectors 
AdV vectors are the most frequently used vectors in gene therapy clinical trials accounting for 22 
% of all trials (http://www.abedia.com/wiley/vectors.php). They are also the most effective 
vectors due to their high transduction efficacy and recognized capability for transducing both 
dividing and non-dividing cells. AdV are highly efficient also in transducing cardiomyocytes, but 
transgene expression is transient, peaking a few days after the gene transfer and lasting for 2-4 
weeks. (Hedman, Hartikainen & Yla-Herttuala 2011, Rissanen, Yla-Herttuala 2007.) The good 
efficacy of angiogenic gene therapy with AdV vectors has been demonstrated in both normal and 
ischemic tissues in both small and large animal models (Lähteenvuo et al. 2009, Huusko et al. 
2010).  
Depending on the dose, potent host inflammatory and immune responses may be encountered 
after the administration of AdV vectors. The acute inflammation is due to the activation of target 
cells and the innate immune system. The majority of humans have circulating antibodies against 
common AdV serotypes and individuals who have been infected earlier develop prolonged 
immunity to the virus, which is common since adenoviruses cause common respiratory infections 
in children. (Chirmule et al. 1999, Zaiss et al. 2002.) 
The inflammatory and toxic effects evoked in response to AdV vector administration are 
mediated through innate and/or adaptive immune responses against the vector. These effects 
may lead to reduced vector transduction, shortened duration of therapeutic transgene expression 
and even to systemic toxicity. Many strategies have been developed in attempts to overcome this 
problem including immunosuppression or immunomodulation of the host, e.g. pre-treatment 
with immunosuppressive agents such as dexamethasone, and more importantly altering the 
vector itself e.g. by modifying the viral capsid. (Ahi, Bangari & Mittal 2011, Thaci et al. 2011.) 
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Although AdV vectors are considered to be rather immunogenic, optimal low doses of AdVs, 
produced according to good manufacturing practice protocols, only cause very little 
inflammation in myocardium and AdVs have been proven to be safe in clinical trials (Hedman et 
al. 2009, Muona et al. 2012, Wirth et al. 2006). The local inflammation produced at the site of the 
gene tranfer is related to the AdV dose (Korpisalo et al. 2011).  
 
2.5.3.2 Adeno-associated virus vectors 
AAV vectors are promising gene delivery vectors which provide long-term transgene 
expression lasting for several months. Unlike wildtype AAVs, genetically modified AAVs are 
able to integrate to the host genome only at low efficiency and randomly, and majority persist in 
cells extra-chromosomally as episomes. (Deyle, Russell 2009.) Several serotypes have been 
characterized displaying differential tissue specificities. AAV serotype 2 (AAV2) has been the 
most commonly used serotype in gene therapy studies but it has shown only a moderate 
transduction efficiency in the heart (Wasala, Shin & Duan 2011, Zacchigna, Zentilin & Giacca 
2014). For cardiac gene transfer, AAV9 is the most efficient AAV vector of serotypes 1-9 and it 
has been reported to efficiently transduce cardiac cells after local and systemic administration in 
rodents (Zacchigna, Zentilin & Giacca 2014). AAV9 has a rapid onset of gene expression both by 
systemic route (Zincarelli et al. 2008) and after direct intramyocardial delivery (Prasad et al. 2011). 
Intramyocardial AAV9 injection has been shown to protect the heart against heart failure in mice 
(Huusko et al. 2012) rats and dogs (Zacchigna, Zentilin & Giacca 2014). There are also other 
serotypes capable of efficiently transducing cardiomyocytes i.e. AAV serotypes 1, 6 and 8 
(Zacchigna, Zentilin & Giacca 2014).  
About 90 clinical trials have been performed using AAV vectors and the first ever gene 
medicine approved for marketing in the western worlds, was the AAV1 vector encoding 
lipoprotein lipase (Glybera) for treating familial LPL deficiency (Wirth, Parker & Yla-Herttuala 
2013, Yla-Herttuala 2012). One clinical cardiovascular trial using an AAV vector proceeded to 
phase 2b and it aimed for heart failure treatment with AAV1 vector expressing sarcoplasmic 
reticulum Ca2+-ATPase (SERCA2a) protein delivered via intracoronary infusion (Greenberg et 
al. 2014, Jessup et al. 2011, Zsebo et al. 2014), but unfortunately it was recently announced that 
the trial failed to achieve positive results (http://www.celladon.com/clinical-trials/cupid-2/, Ylä-
Herttuala 2015). 
AAV vectors do not have any viral genes, they are associated with low immunogenicity and 
have been shown to generate only a limited inflammatory reaction (Rissanen, Yla-Herttuala 2007, 
Zaiss et al. 2002, Gruchala et al. 2004). Preclinical animal studies have not revealed any significant 
immune responses to AAV vectors and no adverse cardiac effects have been reported with 
intramyocardial AAV2 (Meloni  et al. 2012) and AAV9 (Bish et al. 2008, Prasad et al. 2011) 
injections. However, the immunogenicity of AAV has recently become apparent in clinical trials 
and the immune responses are currently profiled more thoroughly in pre-clinical models 
(Hareendran et al. 2013, Basner-Tschakarjan, Bijjiga & Martino 2014). 
Also AAV viral transduction can be limited by both innate and adaptive immunity. The vector 
DNA and the virions can be detected by innate immune response elements, in particular Toll-like 
receptors. In patients, the role of adaptive immune responses is of greater relevance and both pre-
existing antibodies and cytotoxic T-cells may decrease the long-term efficacy of AAV gene 
therapy. Neutralizing antibodies, especially those targetting AAV2, are found naturally in about 
70 % of humans. In clinical trials with AAV vectors, strategies for preventing pre-existing immune 
responses have been used by excluding patients with detectable neutralizing antibody titers or 
by applying mild immunosuppressive pharmacological agents. Another strategy adopted to 
lower the immune response has been to modify the immunogenic capsid epitopes. (Zacchigna, 
Zentilin & Giacca 2014, Ferreira, Petry & Salmon 2014, Zaiss, Muruve 2005.) 
 
27 
 
 
Although AdV vectors are considered to be rather immunogenic, optimal low doses of AdVs, 
produced according to good manufacturing practice protocols, only cause very little 
inflammation in myocardium and AdVs have been proven to be safe in clinical trials (Hedman et 
al. 2009, Muona et al. 2012, Wirth et al. 2006). The local inflammation produced at the site of the 
gene tranfer is related to the AdV dose (Korpisalo et al. 2011).  
 
2.5.3.2 Adeno-associated virus vectors 
AAV vectors are promising gene delivery vectors which provide long-term transgene 
expression lasting for several months. Unlike wildtype AAVs, genetically modified AAVs are 
able to integrate to the host genome only at low efficiency and randomly, and majority persist in 
cells extra-chromosomally as episomes. (Deyle, Russell 2009.) Several serotypes have been 
characterized displaying differential tissue specificities. AAV serotype 2 (AAV2) has been the 
most commonly used serotype in gene therapy studies but it has shown only a moderate 
transduction efficiency in the heart (Wasala, Shin & Duan 2011, Zacchigna, Zentilin & Giacca 
2014). For cardiac gene transfer, AAV9 is the most efficient AAV vector of serotypes 1-9 and it 
has been reported to efficiently transduce cardiac cells after local and systemic administration in 
rodents (Zacchigna, Zentilin & Giacca 2014). AAV9 has a rapid onset of gene expression both by 
systemic route (Zincarelli et al. 2008) and after direct intramyocardial delivery (Prasad et al. 2011). 
Intramyocardial AAV9 injection has been shown to protect the heart against heart failure in mice 
(Huusko et al. 2012) rats and dogs (Zacchigna, Zentilin & Giacca 2014). There are also other 
serotypes capable of efficiently transducing cardiomyocytes i.e. AAV serotypes 1, 6 and 8 
(Zacchigna, Zentilin & Giacca 2014).  
About 90 clinical trials have been performed using AAV vectors and the first ever gene 
medicine approved for marketing in the western worlds, was the AAV1 vector encoding 
lipoprotein lipase (Glybera) for treating familial LPL deficiency (Wirth, Parker & Yla-Herttuala 
2013, Yla-Herttuala 2012). One clinical cardiovascular trial using an AAV vector proceeded to 
phase 2b and it aimed for heart failure treatment with AAV1 vector expressing sarcoplasmic 
reticulum Ca2+-ATPase (SERCA2a) protein delivered via intracoronary infusion (Greenberg et 
al. 2014, Jessup et al. 2011, Zsebo et al. 2014), but unfortunately it was recently announced that 
the trial failed to achieve positive results (http://www.celladon.com/clinical-trials/cupid-2/, Ylä-
Herttuala 2015). 
AAV vectors do not have any viral genes, they are associated with low immunogenicity and 
have been shown to generate only a limited inflammatory reaction (Rissanen, Yla-Herttuala 2007, 
Zaiss et al. 2002, Gruchala et al. 2004). Preclinical animal studies have not revealed any significant 
immune responses to AAV vectors and no adverse cardiac effects have been reported with 
intramyocardial AAV2 (Meloni  et al. 2012) and AAV9 (Bish et al. 2008, Prasad et al. 2011) 
injections. However, the immunogenicity of AAV has recently become apparent in clinical trials 
and the immune responses are currently profiled more thoroughly in pre-clinical models 
(Hareendran et al. 2013, Basner-Tschakarjan, Bijjiga & Martino 2014). 
Also AAV viral transduction can be limited by both innate and adaptive immunity. The vector 
DNA and the virions can be detected by innate immune response elements, in particular Toll-like 
receptors. In patients, the role of adaptive immune responses is of greater relevance and both pre-
existing antibodies and cytotoxic T-cells may decrease the long-term efficacy of AAV gene 
therapy. Neutralizing antibodies, especially those targetting AAV2, are found naturally in about 
70 % of humans. In clinical trials with AAV vectors, strategies for preventing pre-existing immune 
responses have been used by excluding patients with detectable neutralizing antibody titers or 
by applying mild immunosuppressive pharmacological agents. Another strategy adopted to 
lower the immune response has been to modify the immunogenic capsid epitopes. (Zacchigna, 
Zentilin & Giacca 2014, Ferreira, Petry & Salmon 2014, Zaiss, Muruve 2005.) 
 
28 
 
 
2.5.3.3 Lentivirus vectors 
LeV vectors integrate transgenes into the host genome, thereby having the potential for lifelong 
expression of the therapeutic protein in the target cells. LeV vectors have not been widely used 
for cardiac gene therapy, but good efficiency has been achieved in a few pre-clinical trials. 
The first demonstration of LeV transduction in adult rat cardiomyocytes was conducted in an 
ex vivo model with intramyocardial injection of the marker genes green fluorescent protein (GFP) 
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(Halonen et al. 2014). 
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small degree of tissue inflammation with monocytes/macrophages and T lymphocytes was 
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(EGFP) near the injection site. This was suggested to be a response to the vesicular stomatitis 
virus glycoprotein (VSV-G) envelope protein, EGFP, or due to contaminants that had been 
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(http://www.abedia.com/wiley/index.html). More detailed information about indications of 
clinical trials are presented in Figure 10. 
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trial (KAT301), involves the intramyocardial delivery of AdV VEGF-D with the NOGA-catheter 
system in patients with severe CAD and the preliminary results have shown improved perfusion 
and good safety after the gene transfer (https://clinicaltrials.gov/ct2/show/NCT01002430). 
In general, reports indicate that the safety in cardiovascular clinical trials has been excellent 
even in long-term follow-up, but the efficiency needs to be improved (Halonen et al. 2014, Yla-
Herttuala 2013, Hedman, Hartikainen & Yla-Herttuala 2011). 
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Figure 10. Indications of gene therapy trials. Updated in July 2015. (Modified from 
http://www.abedia.com/wiley/indications.php.) 
 
2.5.5 Safety aspects 
Viral vectors may evoke inflammatory or immune responses, which may limit the success of 
gene therapy (Zaiss et al. 2002). In human trials, the most common side-effects associated with 
adenoviral vectors have been the formation of antibodies to adenovirus, transient fever, 
leukopenia and increases in liver transaminases and CRP, but they have not been linked to any 
human malignancies (Yla-Herttuala, Alitalo 2003, Wirth et al. 2006).  
Inflammatory reactions in the tissues are related to the viral dose administered. Therefore the 
use of highly efficient growth factors in angiogenic gene transfer is essential in order to keep the 
viral doses as low as possible (Korpisalo et al. 2011). The viral dose needs to be optimized also 
with regards to the biological effect of the transgene. For example, with VEGF-A gene therapy, it 
has been shown that both the local VEGF-A concentration and the regional blood flow modulate 
the structure of angiogenic vessels i.e. too high local concentrations induce aberrant vascular 
growth (Rissanen et al. 2005, Korpisalo et al. 2011). However, even though the initial response to 
the angiogenic gene therapy with high doses of VEGF are supraphysiological, the formed 
vascular network should be naturally pruned to suit the needs of the target tissue within a short 
period of time (Rissanen et al. 2005, Korpisalo et al. 2011). 
Acute side effects related to angiogenesis, most importantly edema, and rapid changes in 
haemodynamics have been observed in preclinical trials with high doses of VEGF. 
Intramuscularly delivered VEGF-A165 transgene is released from the target tissue and there was 
an increase in the incidence of  side-effects with increasing doses of VEGF and higher degrees of 
induced angiogenesis. (Korpisalo et al. 2011.) Long-term safety concerns have arisen because 
activation of malignancies might be possible due to vector biodistribution, but the experimental 
evidence does not support the concept of growth factor gene therapy promoting neoplasms 
(Muona et al. 2012, Hedman et al. 2009, Isner et al. 2001). The most common morbidity 
encountered after cardiovascular gene therapy has been edema in the lower extremities (Isner et 
al. 2001). 
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3 Aims of the Study 
The aim of this thesis was to develop a clinically relevant high-resolution echocardiography 
guided closed-chest intramyocardial gene transfer method for mice and then to apply the method 
to examine the angiogenic potency and safety of adenovirally delivered VEGF-A, -B and-E (I) and 
to evaluate the effects and safety of intramyovardial gene transfer of AdV-, AAV- and LeV vectors 
(II). Furthermore, a mouse ECG analysis algorithm was developed and validated to improve the 
methodology in subsequent mouse cardiac studies  (III). 
 
In more detail, the aims were 
 
(I) To compare the VEGF-R1-specific ligand VEGF-B186 and the VEGF-R2-specific ligand 
VEGF-E to VEGF-A165, which stimulates both receptors, with regard to their effects on 
angiogenesis and left ventricular function in mice. A new echocardiography-guided 
closed-chest gene transfer method was set up and used for direct intramyocardial delivery 
of the VEGFs.  
 
(II) To compare closed-chest intramyocardial injections of AdV vectors to AAV2-, AAV9- and 
LeV vectors in mouse heart with respect to the transduction efficiency and myocardial 
damage as well as evaluating their effects on the left ventricular function and ECG. Dose-
dependency related effects of AAV9 were also examined by using i.v. injections of three 
different virus doses. 
 
(III) To develop an accurate algorithm for analyzing mouse ECG and validate it by studying 
the ECG findings associated with ageing, pharmacological manipulations (with atropine, 
metoprolol and verapamil), AMI and progressive LVH models. 
 
 
 
In these three studies, setting-up the methodology for cardiac studies in mice, in particular the 
high-resolution echocardiography, the closed-chest intramyocardial injection method and the 
mouse ECG analysis algorithm, aims for easing the translation of the results from the preclinical 
studies into protocols for future phase I clinical trials. 
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4 Materials and Methods 
4.1 EXPERIMENTAL ANIMALS AND DISEASE MODELS 
In all three studies, C57Bl/6J male mice (Harlan Laboratories, Indianapolis, IN) were used as the 
study animals. Mice were group-housed in a temperature- and humidity-controlled environment 
with a 12-hour light/dark cycle in the National Laboratory Animal Centre of University of Eastern 
Finland, Kuopio Campus. Diet and water were provided ad libitum. At the end of the experiments, 
mice were euthanized with carbon dioxide. 
All of the animal procedures were approved by the National Animal Experiment Board of 
Finland and carried out in accordance with the guidelines of the Finnish Act on Animal 
Experimentation. The animal experiments conformed to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 
1996). 
 In studies I and II, the sample size was mainly 6 at a minimum to ensure high enough 
statistical power. When necessary, experiments were repeated to obtain at least 5-6 mice/group 
successfully analyzed at the end. Those mice in which the gene transfer had not been successfully 
performed, were excluded. In study III, the number of mice was decided based on the extent of 
anticipated changes. For instance, ageing was thought to cause fairly small changes in the surface 
ECG and therefore a large number of mice needed to be analyzed in order to detect the changes. 
Instead, in the LAD ligation model of AMI, a smaller number of mice was thought to be sufficient 
since the ECG changes caused by MI are generally more extensive. 
4.1.1 Mouse model of acute myocardial infarction (III) 
A novel, less invasive surgical model of LAD ligation was used to induce acute myocardial 
ischemia (Gao et al. 2010). A small incision was cut in the fourth intercostal space through which 
the heart was gently popped out and the LAD was sutured and ligated using a 6-0 silk suture at 
a site less than 5 mm from its origin. Following the ligation, the heart was immediately placed 
back into the intrathoracic cavity and the muscle layers and skin were closed without the need of 
artificial ventilation. The sham group was subjected to the same surgical procedure without the 
LAD ligation.  
Each MI was confirmed by echocardiographic visualization and histological findings. 
Echocardiography and ECG were registered prior to the operation (baseline), 1, 4 and 8 hours 
and 1, 5, and 21 days post operation. The mice were sacrificed 21 days after the operation and 
hearts were collected for histology.  
4.1.2 Mouse model of progressive left ventricular hypertrophy (III) 
A modified TAC model (Rockman et al. 1991) was used for inducing progressive LVH in mice. 
Mice were anesthetized with s.c. medetomidine (1 mg/kg; Domitor®, Pfizer Inc., NY, USA) and 
ketamine (75 mg/kg; Ketalar®, Pfizer Inc., NY, USA) and intubated with a 0.75 mm polyethylene 
tube for ventilation (MicroVent, Harvad Apparatus, MA, USA). The thorax was opened by 
cutting the sternum from the midline and the transverse aorta was visualized after blunt 
dissection. A 7-0 silk suture was placed around the aorta between the brachiocephalicus and the 
arteria carotis communis sinistra and tied around a 25-G needle, which was subsequently 
removed. Sham operated mice went through a similar surgical operation without the ligation. 
Post-operatively, the mice were given analgesic (carprofen 5 mg/kg s.c.; Rimadyl, Pfizer Inc., NY, 
USA and buprenorfine 0.05-1 mg/kg, s.c.; Temgesic, RB Pharmaceuticals Limited, UK) and the 
antisedative (atipamezole hydrochloride 0.1-1 mg/kg, s.c.; Antisedan, Orion Oyj, Finland). ECG 
was registered at 2 and 4 weeks after the TAC and sham operations. 
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4.2 GENE TRANSFER METHODS 
4.2.1 Gene transfer constructs (I-II) 
For the AdV injections, human clinical grade first-generation serotype 5 replication-deficient, 
E1a/b and E3 deleted preparations were used. In the gene construct, the LacZ transgene had a 
nuclear localization signal (NLS) and was driven by the cytomegalovirus (CMV) promoter. An 
“empty” AdV CMV construct carrying only the CMV promoter without an actual transgene was 
used to assess any possible harmful effects of the LacZ transgene itself. The constucts were 
generated under good manufacturing practice (GMP) conditions in 293T cells and were shown 
to be free from endotoxins and microbiological contaminants (Hedman et al. 2003, Makinen et al. 
2002). Titers of AdV preparations were determined by spectrophotometry (optical density at 260 
nm) as previously described (Laitinen et al. 1998, Puumalainen et al. 1998).  
AAV2 vectors were produced according to a previously described protocol (Zolotukhin et al. 
1999) with some modifications. 293T cells were transfected with the AAV2 vector plasmid with 
calcium phosphate precipitation and the cells were harvested at 48-72 h after the transfection. The 
viral vector was released from cells by three freeze-thaw cycles and the vector-containing media 
purified by iodixanol-gradient centrifugation and heparin-affinity chromatography. The 
fractions containing the purified vector were collected and dialysed against PBS. The purified 
vector was stored in PBS at -70°C until use. The LacZ transgene was under the CMV promoter 
and carried a NLS. 
AAV9 vector production was done in 293T cells using standard plasmid transfection methods. 
Preparations were purified by sucrose-cushion ultracentrifugation and anion-exchange column 
chromatography (Q-Sepharose, GE Healthcare, UK) after which they were concentrated by 
sucrose-cushion ultracentrifugation (Zolotukhin et al. 1999, Gao et al. 2000). The LacZ was under 
the CMV promoter and its expression was cytoplasmic. The titers of AAV viral preparations were 
determined with the qPCR method as described previously (Rohr et al. 2002). Briefly, vector 
genome quantitation was done with real-time qPCR with SYBR green dye and vector-specific 
primers to CMV promoter. A standard curve was generated with plasmid DNA used for vector 
production. 
Third-generation human immunodeficiency virus (HIV)-1-based LeVs were prepared with the 
standard calcium phosphate transfection method in 293T cells as previously described (Koponen 
et al. 2003). The viral preparations were concentrated with ultracentrifugation. The titers of LeV 
vectors were determined with flow cytometry and by measuring the amount of HIV p24 Gag 
antigen by ELISA, as previously described (Koponen et al. 2003). The two methods produced 
results that were the same order of magnitude and for final calculations of the viral dose the 
“functional” titer determined by flow cytometry was used. In the LeV, the green fluorescent 
protein (GFP) transgene was under the human phosphoglycerate kinase-1 (PGK) promoter. 
4.2.2 Echocardiography-guided closed-chest intramyocardial gene transfer (I-II) 
Echocardiography-guided closed-chest injections into left ventricle anterior wall (LVAW) were 
done with the previously described method (Springer et al. 2005) with slight modifications. In all 
gene transfer procedures, mice were anesthetized with isoflurane inhalation (induction: 4.5% 
isoflurane, 450 ml/min air, maintenance: 2.0% isoflurane, 200 ml/min air; Baxter International, 
Deerfield, IL). Injections were conducted with a 30-gauge disposable needle in a 50 µl Hamilton 
syringe connected to a micromanipulator system (Fujifilm VisualSonics Inc., Toronto, Ontario, 
Canada). Under transthoracic echocardiography (TTE)-guidance, the needle was penetrated 
through the chest in between the ribs and it was inserted intramyocardially into the LV wall 
without entering the lumen of the LV. Injections of viral constructs and saline in 10 µl volumes 
were delivered and visualized in TTE images. Carprofen (50 mg/ml, Rimadyl, Pfizer Inc., NY, 
USA) was administered for postoperative analgesia.  
In intramyocardial gene transfers with AdV vectors, a viral dose of 1x1010 viral particles (vp) 
and in AAV2 and AAV9 gene transfers, 1x1010 viral genomes (vg) were used. The dose was chosen 
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based on previous in vivo experiments. In addition, AdV VEGF-A was injected at a 10 times lower 
viral amount of 1x109 vp. Viral preparations were diluted with sterile 0.9% NaCl and injected in 
10 µl volumes. In the LeV GFP gene transfers, 10 µl of non-diluted viral preparation were used 
corresponding to 1-4 x 107 TU. As a control for the effect of intramyocardial injection itself, a group 
of mice received 10 µl sterile 0.9 % NaCl. The mechanical effect of only needle insertion was 
controlled by performing the injection otherwise similarly but without injecting any solution. For 
iv delivery of AAV9 LacZ, three increasing doses were used; 1x1010, 1x1011 and 1x1012 vg in 200 µl 
volumes diluted in saline and injected via the tail vein.  
4.3 METHODS FOR ANALYZING CARDIAC PATHOPHYSIOLOGY 
4.3.1 Transthoracic echocardiography (I-III) 
For TTE mice were anesthetized with isoflurane (induction: 4.5% isoflurane, 450 ml air, 
maintenance: 2.0% isoflurane, 200 ml air, Baxter International, Inc., Deerfield, IL, USA). The TTE 
and ECG recordings were performed with the high-resolution Vevo 770 and Vevo2100 
Ultrasound System designed for small animals (Fujifilm VisualSonics Inc., Toronto, Ontario, 
Canada), using a high-frequency ultrasound probe (RMV-707B in Vevo 770 and MS-400 in Vevo 
2100) operating at 18-38 MHz.  
In studies I and II, the LV dimensions and ejection fraction (EF) were determined from 
parasternal short-axis M-mode TTE images acquired at the mid-papillary level of LV. The value 
of EF was calculated with the Teicholz formula by Vevo software and LV Mass with the formula: 
1.053 x [(LVEDD;d + LVPW;d + LVAW;d)3-LVEDD3], LVEDD, left ventricle end-diastolic 
diameter; LVPW, LV posterior wall; LVAW, LV anterior wall. The left atrium (LA) area was 
determined with the 2D area tool from the parasternal long-axis view B-Mode image taken more 
laterally than the normal long-axis view in order to visualize the LA at its largest projection. In 
addition, the M-Mode projection of aortic root and LA diameter were taken from the same 
orientation. 
In study III in the AMI experiments, the global LV function was assessed with the LV trace 
mode (Vevo 2100) from the parasternal long-axis view B-Mode images. EF in LV trace is 
calculated with the formula EF = 100 * stroke volume / diastolic volume, where stroke volume = 
diastolic volume-systolic volume, where diastolic/systolic volume is V d/s = 7.0 / (2.4 + average 
systolic/diastolic diameter) * (average systolic/diastolic diameter). 
4.3.2 Electrocardiography (I-III) 
The ECG lead II was registered during TTE. The ECG data was exported from the Vevo software 
as raw data format and digital signal processing was performed with in-house software written 
in Matlab (MathWorks, Natick, MA, USA) which was developed for analyzing mouse ECG 
(described in detail in study III). 
P wave duration (intra-atrial conduction) was measured from the onset of the P wave to the 
point where the P wave returned to the baseline; the PQ interval (intra-atrial and atrioventricular 
conduction) from the beginning of the P wave to the beginning of the QRS complex; QRS complex 
(ventricular depolarization) from the beginning of the Q/R wave until the temporal halfway of S 
wave peak and J wave peak; J wave, the wave immediately after the QRS complex (situated 
temporally in the early repolarization); QRSp, the time interval developed herein (ventricular 
depolarization and early repolarization), the time from the beginning of the QRS complex to the 
end of the J wave, which was the point where the J wave returned to the isoelectric line; QT time 
(the duration of ventricular depolarization and repolarization), the time between the start of the 
QRS complex and the end of the T wave, when the curve returned to the isoelectric line or to the 
point where the first derivative of T-wave end became nearly zero; QTc, QT time corrected for 
RR-interval with the modified Bazett´s formula for mice: QTc = mean QT / (RR/100)1/2 (Mitchell, 
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RR-interval with the modified Bazett´s formula for mice: QTc = mean QT / (RR/100)1/2 (Mitchell, 
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Jeron & Koren 1998). Arrhythmias were detected manually from the ECG tracings as premature 
atrial or ventricular complexes, irregular RR-intervals equivalent to atrial fibrillation or wide 
complex tachycardia.   
4.3.3 Myocardial perfusion (I) 
Myocardial perfusion was measured with CadenceTM contrast pulse sequence (CPS) ultrasound 
by Acuson Sequoia C256 using 15L8 probe (Siemens Medical Solutions, Mountain View, CA, 
USA) and a second generation microbubble contrast agent (SonoVuew, Bracco Diagnostics, Inc., 
Princeton, NJ, USA) diluted 1:3 in 0.9 % saline (Rissanen et al. 2008).  
4.3.4 Pharmacological manipulations (III) 
The effects of pharmacological manipulation of the cardiac conduction system were studied with 
2 mg/kg atropine (Atropin 1mg/ml, Takeda Oy, Helsinki, Finland), 2 mg/kg metoprolol (Seloken, 
AstraZeneca, Espoo, Finland) and 5 mg/kg verapamil (Verpamil, Orion, Espoo, Finland). Drugs 
were given as intraperitoneal (ip) injections with saline (0.9% NaCl) injections being used as a 
control. The effects of drugs were monitored with TTE and ECG. 
4.3.5 Effects of isoflurane (III) 
For studying the effects of the inhaled anesthethic isoflurane, the mice were subjected to repeated 
doses of isoflurane once a week for 4 weeks with the same dosage used also with all other groups 
(induction: 4.5% isoflurane, 450 ml air, maintenance: 2.0% isoflurane, 200 ml air, Baxter 
International, Inc., Deerfield, IL, USA) and the outcome was studied with TTE and ECG during 
the anesthesia. 
4.4 HISTOLOGICAL METHODS 
4.4.1 Tissue processing (I-III) 
Before collecting the tissue samples for histology, the tissues were perfused via the LV of the heart 
after puncturing the right auricle with either phosphate-buffered saline (PBS) or 1 % PFA in PBS 
(pH 7.4) and immersion fixed in 4 % PFA in 7.5 % sucrose for 4 hours and kept in 15 % sucrose 
overnight before processing. Tissues were mounted in either paraffin blocks and cut into 5 µm 
thick paraffin sections or in the case of LeV GFP transduced heart samples (II), they were frozen 
to OCT (Optimal Cutting Temperature, Tissue-Tek, Sakura Finetek, Torrance, CA, USA) and cut 
into 8 µm frozen sections. 
4.4.2 Histology and immunohistochemistry (I-III) 
Haematoxylin/eosin (HE) stainings were used to characterize the tissue morphology (I-III). 
Masson trichrome stainings (Masson´s Trichrome, Accustain trichrome stains, Sigma-Aldrich, 
MO, USA) were performed for evaluating tissue fibrosis (I-III). Immunohistological stainings 
were used to evaluate angiogenesis (I), cell proliferation (I), VEGF-R1 and -R2 expression (I) and 
transduction efficiencies (II). Avidin-biotin-horseradish peroxidase system (Vector Elite, Vector 
Laboratories, CA, USA) or alkaline phosphatase (vector Laboratories, CA, USA) wih fuchsin 
(Dako, Denmark) were used as the color substrates. The primary antibodies used are listed in 
Table 2 and the protocols used are described or referenced in more detail in the original 
publications. 
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Table 2. Primary antibodies used in immunohistochemical stainings. 
 
Antibody Structure stained Dilution Manufacturer Study 
 
Lectin 
(Biotinylated Griffonia 
Simplicifolia Lectin I) 
Endothelium 1:100 Vector Laboratories I 
PCNA 
(BiotinPCNA 13-3940) 
Proliferating cells 1:100 Invitrogen I 
Connexin43 / GJA1 (ab11370) Cardiomyocytes 1:2000 Abcam I 
Flt-1 C-17 (sc-316) VEGF-R1 1:200 Santa Cruz 
Biotechnologies 
I 
Flk-1 (14-5821) VEGF-R2 1:200 eBioscience Inc I 
LacZ (Beta-galactosidase) LacZ 1:2500 Merck Millipore II 
GFP (ab 290) GFP  1:1500 Abcam II 
  
4.4.3 Histological evaluations and tissue morphology (I-II) 
Capillary measurements (capillary area, capillary/myocyte, capillary/mm2 and myocyte/mm2 
ratios) were perfomed from five microscopic fields from the affected area at 200x magnification 
from each animal (study I). 
Transduction efficiency (study II) estimated as the number of transgene positive 
cardiomyocytes in intramyocardially injected hearts was quantified from five microscopic fields 
at 400x magnifications from each animal. The size of the transduced area (% of LV area) was 
quantified from 12.5x magnifications. Green fluorescence from LeV GFP transduced hearts was 
evaluated with a fluorescence microscope from frozen sections mounted in Vectashield Hard-Set 
Mounting Medium with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA), which 
counterstains the DNA allowing the visualization of nuclei with  blue fluorescence.  
The size of the injection scar and the amount of fibrosis were determined with blinded scoring 
of HE or Masson trichrome stainings, respectively in the study I. In the study II the scar area size 
in the LV wall (% of LV area) of intramyocardially injected mice was quantified from 12.5 x 
magnified Masson´s trichrome stained sections. Myocardial fibrosis in iv injected mouse hearts 
was analyzed in a blinded fashion by three independent viewers from Masson´s trichrome 
stained microscopic sections (study II). The morphological charasteristics of the injured 
myocardium associated with the intramyocardial and systemic gene transfers was evaluated by 
an experienced pathologist from HE stained heart sections (study II). 
The general histological morphology of safety tissues of AAV9 LacZ intramyocardially and iv 
injected mice was evaluated from HE stained paraffin-embedded sections. The liver samples of 
AAV9 LacZ injected mice were scored by the pathologist (study II). 
All quantifications (capillary measurements, transduction efficiency measurements and scar 
area measurements in studies I and II) were done in a blinded fashion by using AnalySIS software 
(Soft Imaging System, Muenster, Germany). 
4.5 PROTEIN AND GENE EXPRESSION ANALYSES 
4.5.1 Western blot (I) 
The amount of VEGF-E protein in mouse LV after the gene transfer was studied with western 
blotting (antibody C-20, Santa Cruz Biotecnologies Inc., CA, USA). Secondary antibody staining 
was done with the HRP-labeled secondary antibody and visualization with the ECL Plus 
detection system (GE Healthcare, Fairfield, CT, USA). The β-actin primary antibody was used as 
a loading control. 
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4.5.2 ELISA (I) 
Enzyme-linked immunosorbent assay (ELISA) was used to quantify the amount of different 
proteins in the LVAW after gene transfer. Proteins were extracted from snap-frozen samples 
using lysis buffer (T-PER; Pierce Biotechnology, Il, USA) with protease inhibitor (Complete Mini 
proteinase inhibitor cocktail tablets, Roche, Switzerland). The protein concentrations of human 
VEGF-A, mouse VEGF-A, mouse VEGF-R1 and mouse VEGF-R2 were determined with specific 
commercial ELISA kits (Quantikine ELISA Kits, R&D Systems, MN, USA). A human VEGF-B 
ELISA was designed and conducted in Professor Ulf Eriksson´s laboratory.  
4.5.3 Real-time quantitative RT-PCR (II) 
The biodistribution of AAV9 LacZ transgene expression was determined with real-time 
quantitative RT-PCR from the different tissues of AAV9 LacZ iv injected mice and compared to 
the group which received AAV9 LacZ intramyocardially. The studied organs were kidney, liver, 
lungs, spleen, rectus femoris muscle and testis.  
4.6 STATISTICAL ANALYSES 
The statistical analyses were performed with Excel software with Student’s t-test when 
comparing two groups and with GraphPadPrism 6.0 software (GraphPad Software, Inc., La Jolla, 
CA, USA) with one-way analysis of variance with an appropriate post hoc test when comparing 
three or more groups/timepoints. In the follow-up echocardiographic data analyses, repeated 
measures (RM) two-way ANOVA was used. These tests are indicated in the figure legends and 
the following symbols are used to designate the p-value: *p < 0.05, ** p < 0.01, *** p < 0.001. (Studies 
I-III.) Correlations between echocardiographic and ECG measurements were studied with the 
GraphPadPrism 6.0 software by calculating the value of the Pearson correlation coefficient, r 
(study III). 
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5 Results 
This section summarizes selected results from the original publications (marked with I-III) but 
also some unpublished data is included. The main findings of the three publications have been 
combined and do not fully follow the same order as in the original publications. 
5.1 CLOSED-CHEST INTRAMYOCARDIAL GENE TRANSFER METHOD 
An injection method with the high-resolution echocardiography guidance was established to 
permit the closed-chest intramyocardial gene transfer into the LVAW of mice (Figure 11). The 
mice coped the fast injection procedure under isoflurane anesthesia well and there were no 
perioperative deaths.  
 
 
Figure 11. Echocardiography-guided closed-chest intramyocardial gene transfer into mouse heart. 
Short-axis B-Mode view of the LV prior to injection (a), during the injection into the LVAW (b) and 
after the injection (c). The injected liquid produced a white area around the injection point (b, c). 
Unpublished results.  
 
5.1.1 Myocardial damage 
The needle itself or saline injections of 10 µl did not cause notable tissue damage when this 
was evaluated at the 28 days’ timepoint as only a tiny area of inflammatory cells and scar tissue 
representing the needle tract was seen in histology (Figure 18).  
5.1.2 Echocardiography and ECG 
The systolic function measured with EF did not change in the non-treated group exposed only to 
the anesthesia (Echo) or in the group where a plain needle was inserted into the LVAW similarly 
when undertaking the injections but without any liquid being injected (Needle) (Figure 12). 
Unexpectedly, EF was decreased about 25 % at 28 days compared to the baseline after injection 
of saline (NaCl) due to global hypokinesia of the LV (Figure 12, 21).  
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Figure 12. The effects of repeated exposures of isoflurane (Echo), plain needle (Needle) or saline 
injection of 10 µl (NaCl) on ejection fraction. The mechanical trauma caused by the needle or the 
repeated exposures to isoflurane did not have any effect on the EF. After saline injection, the EF was 
decreased at d28. Results are represented as mean ± SD, n=6/group. **p<0.001 compared to Echo 
group according to two-way ANOVA with Dunnett´s post-hoc test. Unpublished results. 
 
The mice from echo, needle and saline groups were imaged with TTE weekly under isoflurane 
anesthesia during the 28 days’ follow-up. As a response to the repeated exposures of isoflurane 
HR increased in all groups (Figure 13 a). In the NaCl group, the HR increase was initially less 
extensive at d6 and d14 compared to echo and needle groups and HR was reduced markedly at 
21d, at the same time when the EF started to decline. The HR increase during 28 d was the largest 
in the Echo group being 27 %. In the needle group, the increase was 20 % whereas the smallest 
HR increase of only 5 % was seen in the saline group (Figure 13 b).  
 
 
Figure 13. Changes in HR after repeated exposures to isoflurane (Echo), plain needle (Needle) or 
saline injection (NaCl) during the follow-up of 28 days. HR changes at different timepoints (a) and 
numerically (b). Results are represented as mean ± SEM, n=6/group. *p<0.05, **p<0.01 compared 
to Echo group according to two-way ANOVA with Dunnett´s post-hoc test. Unpublished results. 
a 
b 
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5.2 BIOLOGICAL EFFECTS OF GROWTH FACTOR GENE TRANSFER  
5.2.1 Angiogenesis and perfusion 
Intramyocardial injections of adenovirally delivered VEGF-B and VEGF-E to an intact mouse 
myocardium induced a more physiological and persistent angiogenic response in comparison to 
the situation in the VEGF-A group. The angiogenic response induced by VEGF-B and VEGF-E 
was seen as regular enlargement of the capillaries and the enlarging process continued from day 
6 until day 14 (Figure 14 g, h, k, l). The morphology of the capillaries showed them to be uniform 
in shape. Instead, VEGF-A induced a drastic enlargement of capillaries at day 6 compared to Adv 
LacZ group, but this effect was only transient as the capillary area was markedly decreased at 
day 14 (Figure 14 e, f, i, j). The greatly enlarged capillaries induced by VEGF-A formed a vascular 
lacunae at day 6, which became surrounded by endothelial cells (Figure 14 f).  
 
Figure 14. Myocardial morphology and capillaries after adenoviral gene transfer of VEGF-A, VEGF-B 
and VEGF-E. VEGF-A induced a strong but transient angiogenic response with lacunae-like endothelial 
cell-surrounded structures (f, j), while the effect was more persistent, physiological and structurally 
uniform in the AdV VEGF-B (g, k) and AdV VEGF-E groups (h, l). Endothelial staining was conducted 
with Lectin I (e-l). Scale bars 100 µm, asterisks indicate the high power insert area. From original 
publication I. 
 
The increase in the capillary areas led to significant increases in perfusion in the LVAW in the 
AdV VEGF-A, AdV VEGF-B, and AdV VEGF-E groups at 6 days after the gene transfer in 
comparison with the AdLacZ control group (Figure 6c, publication I). 
5.2.2 Proliferation 
The profile of proliferating cells was different between the groups (Figure 15 b-f). The total 
number of proliferating cells was significantly higher in AdV VEGF-A group than in the AdV 
LacZ group. In the AdV VEGF-B and AdV VEGF-E groups, a trend towards a higher total cell 
proliferation was seen. In the AdV VEGF-A group, over 90 % of the proliferating cells were 
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endothelial cells (ECs) but in the AdVEGF-B group, the percentage of proliferating ECs was only 
25, with most of the proliferation being in cardiomyocytes. In the AdV VEGF-E group 61 percent 
of the proliferating cells were ECs, and the profile resembled that seen with AdV VEGF-A (Figure 
15 a). 
 
 
Figure 15. The profile of proliferating cells after intramyocardial injection of AdV LacZ, AdV VEGF-A 
and AdV VEGF-B. VEGF-B induced proliferation of cardiomyocytes (a, d and h), while the proliferating 
cells were mainly endothelial cells in VEGF-A (a, c and g) and VEGF-E (a, e and i) groups. Double 
staining (b-e) with lectin (blue) and PCNA (brown), in (f-i) with connexin 43 (brown) and PCNA (blue). 
Scale bars are 10 µm, n=11–13, asterisks indicate the higher power insert area. From original 
publication I. 
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5.3 COMPARISON OF VIRAL GENE TRANSFER VECTORS  
5.3.1 Transduction efficiencies 
Intramyocardial delivery of AdV LacZ (Figure 16 a, e), AAV2 LacZ (Figure 16 b, f), AAV9 LacZ 
(Figure 16 c, g) and LeV GFP (Figure 16 d, h) with a single injection led to local transgene 
expression in the immediate proximity of the needle tract in the LVAW wall (Figure 16 a-d 
arrows). Systemic administration of AAV9 LacZ led to global diffuse transgene expression in the 
whole myocardium (Figure 16 i, j, arrows). AdV was the most efficient vector in delivering the 
transgene into the cardiomyocytes, followed by the equally good AAV2 and AAV9 with the 
smallest transduction efficiency being detected with LeV (Figure 16 k).  
The largest size of the transduced area was observed after intramyocardial AdV and AAV9 
gene transfer, followed by AAV2 and LeV (Figure 16 l). After systemic AAV9 LacZ 1012 gene 
transfer, the transduced area was slightly larger compared to LeV and decreased with decreasing 
viral doses.  
 
 
 
Figure 16. Gene transduction efficiencies in the myocardium 28 days after intramyocardial (a-h) or 
intravenous (i, j) gene transfer. Intramyocardial AdV gene transfer led to the highest transduction 
efficiencies, followed by the equally good AAV2 and AAV9. The smallest transduction efficiency was 
seen with LeV (a-h, k). The largest transduced area size was obtained after intramyocardial AdV and 
AAV9 gene transfer, followed by AAV2 and LeV (l). After systemic AAV9 LacZ 1012 gene transfer, the 
transduced area was slightly larger compared to LeV and decreased with decreasing viral doses (l). 
LacZ stainings from the LacZ transduced groups (a-c, e-g, i, j) and GFP stainings of LeV GFP 
transduced group (d, h) with 10x (a-d, i, scale bar 1000 µm) and 400x (e-h, j, scale bar 50 µm) 
magnifications. Results are presented as mean ± SD (k, l). From manuscript II. 
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5.3.2 Myocardial damage 
 
5.3.2.1 Adenoviral gene transfer of VEGFs 
Myocardial damage as scored from histology was moderate (++) at d6 in all AdV injected groups 
(Figure 17). At d14, the area of inflammatory cells and necrosis was moderate in AdV LacZ, AdV 
VEGF-B, and AdV VEGF-E groups and severe (+++) in AdV VEGF-A group. The myocardial 
damage was similar at d28 in all of the groups apart from VEGF-E in which the damage was 
severe. The damaged area included mostly inflammatory cells in the acute phase (d6) and scar 
tissue together with inflammatory cells were seen at d28. In the saline-injected group, only the 
needle tract with mild damage and inflammatory cells (+) was detected at all time points (Figure 
17). The scar area size at 28 days after the gene transfer was smallest in the VEGF-B group and 
largest in the VEGF-A group (Figure 17 g). LacZ and VEGF-E treatment resulted in similar sized 
scars and by reducing the VEGF-A dose by 10-fold (AdV VEGF-A small), the scar area size was 
reduced by 6,6-fold (Figure 17 g). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
 
 
 
Figure 17. Myocardial damage at 6 and 28 days after intramyocardial adenoviral gene transfer of LacZ, 
VEGF-A, VEGF-B and VEGF-E. Tissue damage assessed from histology was seen as inflammatory cells 
and necrosis at d6-d14 and as scar tissue with inflammatory cells at d28. Tissue damage grading was 
done in a blinded fashion: + refers to mild (needle mark), ++ moderate, and +++ severe damage. 
In the representative histology sections of saline injected myocardium at d6 (a) and d28 (d) only the 
needle mark was detected (arrow) and the damage was graded as mild. In AdV LacZ group at d6 (b) 
and d28 (e) moderate tissue damage and in AdV VEGF-A group at d6 (c) moderate and at d28 (f) 
severe overall tissue damage was present. The quantification of scar area size showed that at 28 d 
after gene transfer, the smallest scar was seen in the VEGF-B group and the largest in the VEGF-A 
group (g). Results are presented as mean ± SD, **p<0.01, ***p<0.001 as compared to NaCl group 
with One-way ANOVA and Tukey´s post hoc test, n=11-13/group. From original publication I and 
unpublished results.  
 
5.3.2.2 Adeno-, AAV- and lentiviral gene transfer of marker genes 
Intramyocardial gene transfer of AdV, AAV2, AAV9 and LeV vectors produced a local fibrotic 
scar area with a lymphocyte-intensive inflammatory reaction at the injection site in the LV wall 
g 
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28 days after the gene transfer (Figure 18 c-f, arrows). The size of the scar area was the largest 
after both “empty” AdV CMV carrying no transgene and AdV LacZ injection, followed by AAV9 
and AAV2 and the smallest scar was seen in the LeV group (Figure 18 a). Only a minimal scar 
area (about 1 % of LV area) representing the needle tract was seen in the Needle and NaCl control 
groups. The amount of scar tissue corresponded to the amount of inflammatory cells within the 
scar area; both AdV gene transfers led to a severe inflammation followed by AAV9 gene transfer. 
After the AAV2 and LeV injections, mild to moderate amounts of inflammation were seen. 
(Figure 18 b.) 
 
 
Figure 18. Myocardial damage at 28 days after gene transfer. Intramyocardial gene transfer caused a 
local fibrotic scar in the LV wall with lymphocyte-intensive inflammatory reaction (c-f, arrows). The 
size of the local scar area in the LV wall (a, quantified from Masson trichrome stained sections) and 
the amount of inflammation at the injection site (b, scored with a 0-3 scale where 0, no inflammation; 
1, minor inflammation; 2, moderate inflammation and 3, severe inflammation) were largest after AdV 
gene transfers, followed by AAV9, AAV2 and LeV. Representative pictures of Masson trichrome stained 
sections of NaCl (c), AdV (d), AAV9 (e) and LeV (f) injected hearts (magnification 10x, scale bar 1000 
µm. From manuscript II. 
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Systemic administration of the AAV9 LacZ with 1012 vg dose led to diffuse fibrosis with 
lymphocyte-rich inflammation throughout the myocardium. In AAV9 1011 and 1010 dose groups 
only minor amounts of fibrosis and inflammation were seen (Figure 2, manuscript II). 
The scar area size was also measured after AAV2 VEGF-A and AAV9 VEGF-A gene transfers. 
The scar was smaller in the AAV2 VEGF-A treated group compared to the AAV2 LacZ treated 
group and a similar trend was also seen in AAV9 injected groups (Figure 19).  
 
 
Figure 19. Scar area size 28 days after the intramyocardial AAV2 and AAV9 gene transfers. Scar size 
was smaller in VEGF-A treated hearts than in LacZ treated hearts. Results are shown as mean ± SD. 
Student´s t-test *p<0.05 compared to LacZ control group; ns, non-significant. Unpublished results. 
 
5.3.3 Echocardiography 
5.3.3.1 Adenoviral gene transfer of VEGFs 
AdV gene transfer of LacZ, VEGF-A and VEGF-E, but not VEGF-B, significantly decreased the 
EF at d21-28 (Figure 20 a). The LVAW thickness was transiently increased after AdV VEGF-A 
gene transfer due to massive edema formation, which coincided with the markedly increased 
capillary area, leading also to transiently increased EF at d6 (Figure 20 b). Instead, AdV VEGF-E 
caused a decreased thickness of LVAW starting at d21 due to the formation of the scar in the 
LVAW. In the other treatment groups there were no significant changes in LVAW thickness 
(Figure 20 b).  
In the AdV VEGF-A group, in addition to the edema at LVAW, four out of six mice (67 %) had 
pericardial effusion at d6, but this was a transient effect, diminishing by d28. One mouse died in 
the AdV VEGF-A group at d 21 after the anesthesia. The mouse had severily impaired systolic 
function together with pericardial effusion. In the VEGF-A group which received a 10x smaller 
virus dose, the edema formation in the LVAW was markedly less severe and no significant 
changes in the LVAW were seen and no pericardial effusion was detected (data not shown). 
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Figure 20. Effects of intramyocardial AdV gene transfers on EF (a) and LVAW thickness (b). EF was 
decreased at d21-d28 in all groups apart from the VEGF-B group (a). Intramyocardial gene transfer 
of AdV VEGF-A resulted in transient edema in the injection site seen as increased LVAW thickness at 
d6-d14 (b). Results are expressed as mean ± SD. One-way ANOVA with Dunnett´s post hoc test, 
*p<0.05 and **p<0.01 compared to day 0 within each group. From original publication I and 
unpublished results.  
 
 
5.3.3.2 Adeno-, AAV- and lentiviral gene transfer of marker genes 
Acute edema at the injection site of intramyocardially injected hearts was seen as an increase in 
LVAW thickness at d6 especially in AdV CMV and AdV LacZ groups (Figure 21 a). Thinning of 
the LVAW at d28 due to fibrosis formation at the injection site was evident in the LacZ group at 
d28 (Figure 21 a, d, g). AdV LacZ caused LV dilatation (Figure 21 d, g) and systolic dysfunction 
at d28 (Figure 21 b). Neither of the locally injected AAV serotypes nor LeV impaired the LV 
systolic function (Figure 21 b). Instead, systemic AAV9 LacZ 1012 gene transfer led to significantly 
impaired LV systolic function (Figure 20 b, e, h). Surprisingly, LV dilatation and a significant 
decrease in LV systolic function were also seen in the NaCl injected group (Figure 21 b, c, f).  
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Figure 21. Echocardiographic measurements of LVAW thickness and EF after AdV, AAV2, AAV9 and 
LeV gene transfers. Diastolic LVAW thickness (a) and ejection fraction (b). Representative B-Mode 
(long axis view) and M-Mode (short axis view) images of intramyocardially injected NaCl (c, f), AdV 
LacZ (d, g) and iv injected AAV9 LacZ 1012 (e, h) before the gene transfers at day 0 (D0) and at 28 
days after the gene transfer (D28). Increased LVAW thickness indicating edema at the injection site 
was seen especially in the AdV injected hearts (a). EF was decreased 28d after NaCl, AdV LacZ and 
AAV9 LacZ iv 1012 injections (b). Results are expressed as mean ± SD. One-way ANOVA with Dunnett’s 
post hoc test (a) or Student´s t-test (b) were used, *p<0.05, **p<0.01, ***p<0.001 compared to 
day 0 value within each group. LV, left ventricle; LVAW, LV anterior wall; LVPW, LV posterior wall; 
LVEDD, LV end-diastolic diameter. From manuscript II. 
 
5.3.4 ECG 
HR increased during the 28 days’ follow-up in all groups. The HR increase in gene transfer groups 
was on average 54 bpm (13 %) and the RR decrease was on average 17 ms (12 %). NaCl injections 
did not induce any major changes in the ECG at d28 (Figure 22 b, c), even though the PQ interval 
slightly shortened and S amplitude slightly increased possibly due to higher HR and increased 
LV volume, respectively. A decreased R amplitude was observed after intramyocardial gene 
transfer of AdV CMV, AdV LacZ and LeV GFP (Figure 22 a); this most likely can be explained by 
the presence of scar tissue. The most extensive ECG changes were seen after systemic AAV9 LacZ 
1012 dose treatment as the durations of the P and Q waves increased and P, R and S wave 
amplitudes decreased at d28 (Figure 22 a, d, e), which might result from increased LA size and 
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LV fibrosis. In addition, some signs of repolarization abnormalities were seen, reflected as the 
disappearance of the J wave and JT depression in 50 % of the mice at d28 (Figure 22 e).   
 
 
 
Figure 22. The ECG results after AdV, AAV2, AAV9 and LeV gene transfers (a). Representative ECG at 
baseline (Day 0) and at 28 days after intramyocardial injection (Day 28) in the saline group (b, c) and 
the systemic AAV9 1012 dose group (d, e). R wave amplitude was decreased 28d after intramyocardial 
AdV and LeV gene transfer (a), otherwise there were no marked changes in the ECG. Systemic AAV9 
LacZ 1012 gene transfer resulted in increased P and Q wave durations, decreased P, R and S amplitudes 
(a) and to repolarization abnormalities (d, e). Results are shown as mean ± SD. Student´s t-test 
*p<0.05, **p<0.01, ***p<0.001 compared to day 0 value within each group. P dur, duration of P 
wave; Q dur, duration of Q wave; Amp, amplitude. Number of mice in each group is indicated in the 
heading. From publication III and unpublished results.  
5.4 MOUSE ECG ANALYSIS  
5.4.1 ECG findings during ageing 
The HR, P wave duration, PQ interval time and QRSp duration increased during ageing in 
C57Bl/6J mice, whereas, Q duration and R amplitude decreased as measured from the recorded 
lead II (Figure 23). 
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Figure 23. ECG findings in 2-3 months old (Young), 12-14 months old (Middle-aged) and 20-24 months 
old (Old) C57Bl/6J mice. Ageing led to increased P, PQ and QRSp duration and to decreased Q duration 
and R amplitude (a-d). Representative ECG curves of young (b), middle aged (c) and old (d) mice 
with appropriate ECG intervals marked. From publication III. 
 
 
The LV wall thicknesses (LVAW and LVPW) and consequently LV mass was increased during 
ageing, but there were no changes in LVEDD, LV volume or ejection fraction. In addition, the 
aortic root dimension and LA area were increased in middle-aged and old mice (Figure 1, 
publication III). The prevalence of arrhythmias and a longer PQ interval increased during ageing 
(Figure 2, publication III).  
5.4.2 ECG changes after acute myocardial infarction 
After LAD ligation, an antero-apical AMI developed and this induced an elevation in the JT 
segment at 1h-8h, which was associated with a rise of the J wave and a marked decrease in S  
amplitude (Figure 24 a-e). After the JT elevation became lowered, changes in the JT/T segment 
were seen; the J wave had widened at d5 and there was JT depression/Twave inversion seen 
starting at d14 (Figure 24 g). There was the appearance of non-physiological Q waves starting at 
4h after the AMI, when the duration of the Q wave was significantly increased (Figure 24 a, d-g). 
The R amplitude was decreased starting from 4h (Figure 24 a, d-g). There was a transient increase 
in QT/QTc time, similarly to that seen in the sham treated group (Figure 4, publication III).  
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Figure 24. ECG changes in acute myocardial infarction caused by LAD ligation. The ECG measurements 
after AMI (a) and representative ECG curves (b-g). As a consequence of an AMI, the JT segment was 
elevated, pathological Q waves developed and R waves diminished. In addition, JT/T abnormalities 
were seen. n=6 mice/group. From publication III. 
 
5.4.3 ECG changes occurring in progressive left ventricular hypertrophy 
In the progressive LVH model induced by TAC, concentric hypertrophy with slightly decreased 
LVEDD was seen at the two week timepoint. At 4 weeks, LVH had progressed to the eccentric 
hypertrophy phase with increased LV wall thickness, dilated LV and decreased EF of 58 % in 
comparison to 75 % in sham operated mice. The LV mass increase was 14 % at 2 weeks and 34 % 
at 4 weeks. No changes were seen in the left atrium diameter (Figure 5, publication III).  
The widths of QRS and QRSp were increased at the 2 week timepoint and especially 4 weeks 
after the TAC operation (Figure 25 a). There was no significant changes in the R amplitude 
(although it was slightly increased at the 2 weeks’ timepoint) (Figure 25 a). In addition, 
repolarization abnormalities were evident as changes in J wave (widening and/or lowering), were 
seen in approximately 50 % of mice after the TAC operation (Figure 25 b-e). 
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Figure 25. Electrocardiographic changes associated with progressive left ventricular hypertrophy 
induced by the TAC operation. The durations of QRS and QRSp were increased, but no significant 
changes were seen in R amplitude (a). In addition, repolarization abnormalities evident as changes in 
J wave (widening and/or lowering), were seen in approximately 50 % of mice (b-e). Results are 
expressed as mean ± SD. Student´s t-test was used, *p<0.05, **p<0.01, ***p<0.001 compared to 
the sham operated group at the same timepoint. n=8-10 mice/group. From publication III. 
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6 Discussion 
6.1 CLOSED-CHEST INTRAMYOCARDIAL GENE TRANSFER 
Mouse models have become increasingly important in studying human diseases and the 
characterization of mouse phenotypes is a topic of major importance. Lately, high-resolution 
echocardiography systems have been developed for mice and they have proved to be beneficial 
in attaining an accurate assessment of cardiac function in vivo. In preclinical and clinical gene 
transfer trials, it has been demonstrated that local delivery of the gene drug is more efficient and 
produces less side-effects compared to its systemic delivery (Yla-Herttuala 2013, Hedman, 
Hartikainen & Yla-Herttuala 2011, Korpisalo et al. 2011, Hiltunen et al. 2000). In this thesis, a high-
resolution echocardiography system was set up for mice and a closed-chest intramyocardial gene 
transfer method was established; this technique was found to be feasible and effective.  
Mouse HR during isoflurane anesthesia is about 400-500 bpm and therefore it would be 
expected that inserting a stationary needle into the rapidly beating myocardium while making 
the injections would harm the myocardium. But in fact, the histological evaluation revealed that 
the tissue damage caused by plain needle insertion was very minimal and it did not exert any 
effect on LV function or ECG. The injections are conducted very quickly, in less than 30 seconds 
by an experienced researcher, which minimizes the tissue damage. In addition, since the animals 
are monitored by echocardiography, the needle can be guided accurately to the desired injection 
spot. The injection can be clearly visualized due to the appearance of a white spot around the 
injection site in the LV wall, which maximizes the success of gene transfer and minimizes any off-
target effects. 
Furthermore, the saline injections did not cause any significant myocardial damage, but for 
some unknown reason, LV dilatation and global LV hypokinesia was seen although it did not 
lead to any major effects on ECG. The only clear difference between the saline group with the 
other control groups (Needle and Echo) was that the HR increase occurring after repeated doses 
of isoflurane was clearly smaller in the saline treated group than in the other groups. In addition, 
when taking the gene transfer groups (AdV, AAV and LeV) into account, the HR increase was 
the smallest in the saline group but nonetheless this was the only group in which the PQ time 
was significantly decreased at d28 compared to d0. As far as is known, there are no reports 
describing the effects of intramyocardial saline injection on LV function, but after systemic 
delivery of saline in mice, no changes in the LV function were seen (Zincarelli et al. 2008). 
Previously, direct intramyocardial injection of viral buffer has been shown to cause a mild 
inflammatory response in mouse heart (Vassalli et al. 2003), consistently with the present results. 
Several different methods can be used for delivering the gene product into myocardium, 
ranging from systemic delivery via the mouse tail vein to sophisticated local delivery methods 
used in large animal models and in human trials (Katz et al. 2012, Katz et al. 2013, Ishikawa et al. 
2013). For intramyocardial delivery, direct local intramyocardial injections requiring 
thoracotomy are most often used in pre-clinical studies, although the trend in clinical trials has 
been to move to using mostly percutaneous intramyocardial injection or intracoronary infusion 
methods (Halonen et al. 2014). Thoracotomy itself causes damage leading to induction of repair 
processes and the expression of endogenous growth factors in young and healthy animals 
(Markkanen et al. 2005). With the minimally invasive closed-chest injection method devised here, 
it is possible to avoid the traumatic open-chest procedures. 
The devised injection method resembles the clinical procedure of catheter-mediated 
percutaneous intramyocardial injection method (Katz et al. 2012) as both are minimally invasive 
and no traumatic thoracotomy is needed in either of the procedures. However, in the present 
method, the injections are made epicardially and the pericardial sac is therefore disrupted which 
differs from the catheter-mediated endocardial injection techniques conducted in clinics. 
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However, there was no evidence of pericardial effusion in any of the mice during the follow-up 
apart from the AdV VEGF-A group, which will be discussed later. 
6.2 TRANSDUCTION EFFICIENCY 
 
Viral vectors with different transgene expression profiles are needed for different therapeutic 
settings. If one considers the situation where a rapid restoration of  tissue perfusion after an acute 
coronary occlusion is needed, it is clear that one requires a delivery technique with a rapid, high 
transduction efficiency. In such a situation, the preferable choice would be adenoviruses, which 
have high transduction efficiency and transgene expression is transient, lasting 2-3 weeks in 
larger mammals with a normal immune system, which should be sufficient time to induce 
angiogenesis and increase tissue perfusion (Markkanen et al. 2005), as shown also in this thesis. 
The main reasons for the short duration of AdV transgene expression are the direct toxicity of the 
viral capsid and the immune responses generated to AdV gene products (Vassalli et al. 2003). The 
transduction efficiency of about 40 % in the immediate proximity of the needle tract after AdV 
gene transfer is in line with the previous findings from our group, since the transduction 
efficiency was estimated to be about 50 % close to the needle tract after intramyocardial AdV 
injection into pig heart (Lähteenvuo M. et al unpublished results). Similar transduction 
efficiencies have been also observed in mice after AdV LacZ gene transfer with the same closed-
chest injection method (Toivonen et al. 2012). 
Instead, the collateral growth and arterialization of neovessels require longer transgene 
expression lasting for several weeks to months, which can be achieved by using episomal vectors, 
like AAVs or vectors integrating into the host cell genome, like LeVs. AAVs have been shown to 
have a lower transduction efficiency in cardiomyocytes compared to adenoviruses (Vassalli et al. 
2003), which is consistent with the present findings. On the other hand, AAV vectors do not 
contain any viral genes and therefore do not generate immune responses against viral gene 
products and furthermore, transgene expression can last for up to a year after AAV gene transfer 
in skeletal muscle and myocardium (Vassalli et al. 2003, Karvinen et al. 2011). 
The main limitation for using LeV in cardiovascular approaches has been the low transduction 
efficiency and low titers of virus preparations (Rissanen, Yla-Herttuala 2007). This is consistent 
with the present findings and the low titers were the reason for the use of lower viral dose of LeV 
vector compared to AdV and AAV. In addition, it was not possible to produce high enough LeV 
titers with the LacZ gene which is larger in size than the GFP gene, and therefore it was necessary 
to use a different marker gene with the LeV injections than in the AdV and AAV gene transfers. 
Thus, it is more difficult to compare the LeV group to the AdV and AAV groups in which the 
transgene and the promoter were the same and the same amounts of viral vectors were injected. 
In addition, in the LeV construct, the GFP gene was driven by the PGK promoter and the CMV 
promoter has been shown to drive higher EGFP expression levels than the PGK promoter with 
LeV vectors in adult rat cardiomyocytes (Fleury et al. 2003). Therefore, the use of a stronger 
promoter, like CMV, possibly combined with higher concentration viral preparations, could well 
improve the LeV transduction efficiency. In view of these considerations, one can state that the 
transduction efficiency of about 11 % after LeV gene transfer in the maximally transduced area 
of the LV with the dose of only 1-4 x107 TU was rather good. Similar transduction efficiencies 
have been reported after intramyocardial injection of LeV EGFP in rats (Fleury et al. 2003) and 
higher transduction efficiencies reported in an ex vivo model after LeV GFP and -LacZ gene 
transfer (Zhao et al. 2002) and in normal rat heart after hypothermic intracoronary delivery of 
LeV-EGFP (Niwano et al. 2008). Therefore, it would be interesting to study further the potential 
of LeV, although first some modifications to the vector will be needed in order to achieve more 
efficient transgene expression. Also, the vector production system will need to be improved in 
order to gather more concentrated viral preparations.  
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6.3 ADVERSE EFFECTS CAUSED BY VIRAL GENE TRANSFER 
Considerable myocardial damage was evident after viral gene transfers, especially after 
intramyocardial AdV injections and systemic AAV9 injections. It is generally known that AdV 
vectors provoke immune reactions. In clinical trials, AdVs have caused inflammatory reactions, 
transient fever and the formation of neutralizing antibodies (Wirth et al. 2006). The adverse side-
effects associated with AdV gene transfer are very dose-dependent and mediated also in off-
target tissues via blood and lymphatic vessels after intramuscular gene transfer (Korpisalo et al. 
2011). Dose-dependency was also observed in the present studies, since a 10-fold lower dose of 
AdV VEGF-A evoked clearly smaller damage, but unfortunately also the angiogenic effect was 
markedly decreased.  
In contrast to AdVs, AAVs have been generally thought to have low immunogenicity. After 
intramyocardial delivery of AAV serotypes 1, 2, 5, 6, 7 or 8, no neutralizing antibodies were 
detected (Palomeque et al. 2007). The systemic administration of AAV9 vector has been reported 
to achieve efficient transduction of cardiomyocytes in small animals (Zincarelli et al. 2008, Bish et 
al. 2008, Inagaki et al. 2006), but no major adverse effects have been reported. Therefore, the 
severe diffuse fibrosis generated with the systemic AAV9 1012 vg dose, which is a generally used 
dose, was a surprising finding. Systemic administration of AAV9 is not a feasible method for 
human studies (Rissanen, Yla-Herttuala 2007), but as it is frequently used in preclinical studies 
with small animals, the harmful effects need to be taken into account when interpreting the effects 
of the gene transfer. 
In general, the adverse effects of viral vectors to the myocardium have not been reported in 
gene transfer studies. After intramyocardial AAV2 injection with a viral dose of 1 x 1011 vp 
(Meloni et al. 2012) or intramyocardial AAV9 injection with a viral dose of 5 x 1010 vg (Prasad et 
al. 2011), no toxic effects to the myocardium were reported, even though the viral dose was larger 
than in the present study. Considering the size of the mouse, the virus doses used in this thesis 
were fairly high, although they resembled those often administered. In addition, the interspecies 
differences have to be kept in mind, since mouse, rat and pig tissues are much less prone to AdV 
gene transfer than human and rabbit tissues (Rissanen, Yla-Herttuala 2007). In comparison, in a 
swine model where AdV gene transfers were delivered intramyocardially with a NOGA catheter, 
1x1012 vp was used in 10 injections of 0.1 ml and no major tissue damage was seen apart from the 
needle tract (Lähteenvuo et al. 2009, personal communication). In an ongoing clinical trial for the 
treatment of severe CAD (KAT301), the same intramyocardial method has been used for 
delivering the VEGF-D gene with AdV with the doses of 1x109, 1x1010 and 1x1011 vpu of virus in 
10 injections of 0.2 ml. Based on preliminary results, the treatment has been assessed as both safe 
and well tolerated (personal communication with Professor Seppo Ylä-Herttuala). In most human 
trials, 4x1010 particle units have been used and the doses have been well tolerated (Wasala, Shin 
& Duan 2011). Although mouse models are invaluable in understanding the biological function 
of transferred genes, information derived from small animal models should be extrapolated with 
caution to human therapies. 
Interestingly, with AdV, the scar area was larger after AdV VEGF-A gene transfer compared 
to empty AdV CMV and AdV LacZ marker gene transfer and this was different from the situation 
after AAV2 and AAV9 gene transfers, where the VEGF-A expression seemed to be beneficial and 
the scar area size was smaller than in LacZ groups. This might be explained by the fact that with 
AdV vector, the expression of VEGF-A and the following edema formation was more extensive 
and therefore a larger area was damaged. Instead, with AAVs, the expression levels are lower 
and therefore VEGF-A may actually reduce the harmful effects exerted by the viral vector itself. 
The main issue with the viral gene transfers is to make the viral dose as small as possible in 
order to reduce the non-desired adverse effects, but there has to be high enough expression of the 
gene product in order to obtain the biological effects. Therefore, less immunogenic vectors and 
maximally potent growth factors are required. With the present method, the LeV induced only 
minimal tissue damage and therefore it would be interesting to fully evaluate the potential of LeV 
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6.3 ADVERSE EFFECTS CAUSED BY VIRAL GENE TRANSFER 
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vectors. Here only one injection was given but one way by which the low transduction efficiency 
could be increased would be to undertake multiple injections, which is also possible with the 
novel gene transfer technique.  
In this thesis, injections were only made into intact non-diseased hearts, but the method could 
be applied also for testing gene transfer approaches in AMI. With the high-resolution 
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for the first time in the myocardium. Therefore, it can be concluded that with the AdV dose used, 
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is assessed with the increased capillary area size and increased myocardial perfusion.  
A gene delivery method can be considered optimal when it achieves good transgene 
expression in the target tissue and low expression in non-target tissues (Hiltunen et al. 2000). As 
a consequence of intramyocardial gene transfer of AAV9 LacZ, only a small amount of transgene 
expression was detected in some of the safety tissues, especially liver; this was not unexpected 
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tissues examined (so-called safety tissues) was always extremely low, especially in comparison 
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in the liver. Therefore, it can be concluded that with the AAV9 LacZ vector used here, the 
biodistribution of the transgene administered by the closed-chest intramyocardial injection 
method was acceptable. Instead, some concerns would be raised by the levels of LacZ expression 
in safety tissues after systemic AAV9 delivery, especially with the highest dose used. However, 
with different virus serotypes possessing different tissue tropisms and with different gene 
delivery techniques, the biodistribution might be different and therefore it is recommended to 
evaluate the consequences of transgene expression in non-target tissues. The safety of gene 
therapy can be improved by using tissue-specific and regulated promoters in the transgene 
construct (Hiltunen et al. 2000). 
6.4 BIOLOGICAL EFFECTS OF VEGFS 
The angiogenic response in intact heart differs from ischemic tissue, since the effect of VEGF gene 
therapy depends on regional hemodynamics (Rissanen et al. 2005, Yla-Herttuala 2006). In tissues 
with a normal blood flow, the most prominent effect of VEGF gene therapy is dilation of the 
existing capillaries, as seen in the present study (I). Instead, when the blood flow is reduced or 
absent, sprouting angiogenesis is more prominent. In addition, in intact muscles with low VEGF-
A concentrations, capillary sprouting is induced with no beneficial metabolic effects. Instead, 
higher VEGF-A concentrations are needed for inducing capillary enlargement, which is then 
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accompanied by increased tissue perfusion and improved aerobic energy metabolism (Korpisalo 
et al. 2011). Therefore, a sufficiently high viral dose was chosen here, making it possible to reveal 
the biological effects of the particular growth factor. 
The effects of growth factors were studied in normal intact myocardium in order to assess how 
the individual growth factor and virus vector would induce endogenous responses of vascular 
growth, necrosis and inflammation without this being complicated by the presence of ischemia. 
For this reason, normal tissues are recommended for the first proof-of-principle experiments. 
(Rissanen, Yla-Herttuala 2007.) In addition, when choosing a potent angiogenic factor, it should 
induce blood vessel growth in both normoxic and ischemic tissues. Especially, when the goal of 
the gene therapy is to induce arteriogenesis, it is essential to use growth factors that are also 
potent in tissues without hypoxia, since the collateral growth occurs in the normoxic myocardium 
proximally to the occlusion site. (Markkanen et al. 2005.) 
The most striking acute effects were seen after AdV delivery of VEGF-A, which evoked marked 
transient edema at the injection site at 6 days after the injection and transient pericardial effusion 
in 67 % of the mice. No deaths were seen after gene transfers in mice, apart from one mice injected 
with AdV VEGF-A, which died during anesthesia at 21 days after the gene transfer. The systolic 
function of that particular mouse was severely impaired and marked pericardial effusion was 
seen. With the ten times lower AdV VEGF-A virus dose, only very mild edema in the LVAW was 
seen with no pericardial effusion. It is well known that the most important side effect of AdV 
gene transfer of VEGF is transient edema and accumulation of free fluid in the pericardial sac. 
The edema coincides with the peak perfusion effect at about 6 days after the AdV gene transfer 
and it is dose dependent (Hedman, Hartikainen & Yla-Herttuala 2011, Yla-Herttuala et al. 2007, 
Korpisalo et al. 2011). In the pig myocardium, percutaneous intramyocardial administration of 
AdV itself caused only mild inflammation and no effusion, but high doses of the AdV VEGF-A 
gene resulted in pericardial effusion (Rutanen et al. 2004). 
The growth of blood vessels requires action of several growth factors and overexpressing only 
one factor may not produce an optimal response. Therefore, a combination of growth factors or 
a factor which is capable of up-regulating other factors should be used in order to obtain optimal 
results. One of the reasons why VEGFs are considered so potent in angiogenic gene therapy is 
that binding of VEGFs to their receptors leads to signaling cascades producing many different 
effects.  Based on the present and previously published results (Lähteenvuo et al. 2009), VEGF-B 
can be considered as a cardiac-specific angiogenic factor which exerts several effects on 
angiogenesis and metabolism and causes the least adverse effects. Thus, it seems to be the most 
beneficial growth factor of the tested VEGFs in mouse heart.  
6.5 ECG ANALYSIS ALGORITHM FOR MICE 
Surface ECG is the primary tool in diagnosing patients with heart disease. Mice have become 
important models for studying molecular and genetic factors in cardiovascular diseases, 
especially due to the ever-expanding number of genetically modified mouse models. The mouse 
ECG is still a widely unexplored field and little is known about the relationship of mouse surface 
ECG to physiological and pathological changes in the heart. Reliable characterization of clinically 
relevant electrophysiological parameters is challenging in mice due to their small size, extremely 
rapid HR and differences in surface ECG in comparison to man. In addition, very few mouse 
ECG analysis systems are readily available. Accurate and repeatable measurements of ECG are 
of great importance for characterizing mouse models and to allow translation of the results to the 
human disease situation. Therefore, there was a clear need to develop an ECG analysis algorithm 
for mice. The high resolution echocardiography system used in this thesis is becoming widely 
used in small animal experimentation and offered the possibility to record the raw surface ECG 
signal (lead II) simultaneously with the echocardiography. Taking these issues into consideration, 
we decided to develop an algorithm which would enable a detailed analysis of the mouse ECG. 
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The developed ECG analysis algorithm was validated with the most widely used C57Bl/6J 
mouse strain. Surface ECG and simultaneously recorded echocardiographic findings were 
studied in ageing heart, after administration of drugs generally recognized as affecting the 
conduction system (atropine, metoprolol and verapamil) and in AMI and progressive LVH 
models. 
In the ageing mouse heart, the prevalence of arrhythmias (premature atrial and ventricular 
complexes), P wave duration, PQ interval and QRSp duration were increased and R wave 
amplitude decreased. Furthermore, slight changes were seen in QRS complex morphology. These 
are consistent with the ECG findings in ageing human heart (Fleg et al. 1990, Kelley et al. 2006, 
Heikkilä, Mäkijärvi 2003). The ECG changes in the course of ageing have not been studied this 
extensively before in such a large number of mice. In fact, only a few of these changes have been 
previously described in mice, namely an increased P wave duration and susceptibility to atrial 
fibrillation in Kunming mice (Luo et al. 2013) and increased PQ interval in C57Bl/6J mice (Chaves 
et al. 2003).  
The basic ECG parameters not only vary extensively between different mouse strains but also 
to the presence of anesthetics (Kaese, Verheule 2012, Wehrens, Kirchhoff & Doevendans 2000). 
The PQ (or PR) interval, QRS duration, QT and QTc measured with the devised algorithm are 
well within the range of previously described findings summarized by Kaese and Verheule 
(Kaese, Verheule 2012). The changes caused by isoflurane have been studied in C57Bl/6J mice 
with telemetry (lead II) and they included decreased HR (from 747 to 536 bpm) and increased QT 
interval (from 45 to 63 ms) but no changes in J- and T wave amplitudes were seen 
(Speerschneider, Thomsen 2013). In the present study, the HRs during isoflurane anesthesia were 
somewhat lower being approximately 420-480 bpm and QT times were 46-48 ms. 
Based on the results obtained from ECG analysis algorithm in this thesis, the ECG reference 
values for different aged C57Bl/6J mice are depicted in Table 3.  
 
Table 3. The reference values for ECG parameters in young (2-3 months old), middle-aged (12-14 
months old) and old (20-24 months old) C57Bl/6J mice. 
  
Young 
 
  
Middle-aged 
 
  
Old 
 
PQ (ms) 44 ± 3  50 ± 17  60 ± 24 
QRS (ms) 11 ± 1  11 ± 1  11 ± 1 
QRSp (ms) 16 ± 2  16 ± 1  18 ± 2 
QTc (ms) 40 ± 4  42 ± 3  41 ± 4 
 
In humans, a PQ interval longer than 200 ms is considered as first degree AV block (Thaler 
2010). As far as is known, the diagnostic criteria for first degree AV block have not been 
determined for mice. Therefore, it was intriguing to consider whether one could define a possible 
upper limit for a  normal PQ interval. No PQ interval durations above 55 ms were detected in 
healthy young mice. When the PQ interval increased markedly in some middle-aged and old 
mice, namely above 82 ms, the P wave was superimposed on the T wave of the previous complex. 
Previously it has been reported that the normal range of the PQ time in mice is 30-56 ms (Kaese, 
Verheule 2012). Based on these findings, it could be proposed that the upper limit for normal PQ 
time might be 60 ms and a PQ time above 60 ms would be equivalent to a first degree AV block. 
With this criterion, the prevalence of the first degree AV block in C57Bl/6J mice would be 12 % in 
the middle aged group and 25 % in the old mice group, which is comparable to the situation in 
elderly human populations where a prevalence of 16-17 % has been reported (Lakkireddy, Clark 
& Mohiuddin 2003, Kelley et al. 2006).  
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Commonly used drugs affecting the conduction system, namely atropine, metoprolol and 
verapamil, altered the cardiac electrophysiology mainly as expected. Metoprolol and verapamil 
decreased the HR and increased the PQ interval. Verapamil had a smaller effect on HR but a 
stronger effect on the PQ interval than metoprolol, as in humans (Koulu, Tuomisto 2007). In 
contrast to the findings here, previously in C57Bl/6J mice with twice as large a dose of verapamil, 
an increase in HR was seen, although similarly as here, the PQ interval was increased 
(Speerschneider, Thomsen 2013). Atropine decreased the PQ interval time as expected (Koulu, 
Tuomisto 2007) but it did not seem to increase the HR any more than the saline injections. In 
contrast to humans, the sympathetic tone is predominant in mice and parasympathetic blockade 
(atropine) does not increase the HR whereas sympathetic blockade (metoprolol) is known to 
evoke a pronounced decrease in HR (Kaese, Verheule 2012), which is consistent with the findings 
in the present study. 
As far as is known, there are no studies which would have examined as thoroughly the mouse 
ECG findings after LAD ligation at as many timepoints as in this study. The ECG findings 
associated with AMI in C57Bl/6J mice included early JT elevation, marked reduction in S 
amplitude, pathological Q waves, decreased R wave amplitude and later changes in JT/T 
segment. Some of these changes have been described previously in CD2F1 mice (Wehrens, 
Kirchhoff & Doevendans 2000) and in FVB mice (Gehrmann et al. 2001). In C57Bl/6J mice, 10 
minutes after LAD ligation, no clear JT segment elevation was seen, but instead a JT segment with 
positive large T wave (Speerschneider, Thomsen 2013). Boukens et al. interpreted this to mean 
that AMI in mice was not seen as ST elevation but as a reduction in the S amplitude (Boukens et 
al. 2014). In the present study, the S amplitude reduction was also seen in sham operated mice, 
although to a lesser extent than in the MI group. Therefore, the JT segment elevation was 
considered as a more specific finding for early AMI in mice and corresponding to ST elevation in 
humans.  
There seems not to be any published reports describing the criteria for a pathological Q wave 
in mice. In fact, no studies conducted in mice providing numerical values of Q wave duration or 
P, Q, R and S amplitude measurements of surface ECG were found. The pathological Q waves 
seen in human AMI are wider and deeper compared to physiological septal Q waves and they 
are usually > 0.03 seconds and > 0.1 mV deep (Thygesen et al. 2012). Here the Q wave duration in 
normal mice was below 2 ms on average and the highest single value found in normal mice in 
this study was 3.6 ms; this value was detected in a young mouse. Four hours after AMI, the 
pathological Q waves started to develop and the average Q duration at that point was 4.9 ms. 
Thus it seems that the limit between physiological and pathological Q wave duration in mice 
after LAD ligation is around 4 ms, when this is assessed from the lead II. 
As far as is known, the surface ECG changes in the compensatory phase of LVH in the widely 
used TAC model have not been earlier characterized in mice to this extent. The QRS complex 
widening in this study has also been observed in human LVH (Thaler 2010, Iuliano et al. 2002) 
and has also been described in mice (Boulaksil et al. 2010). The size of the heart and impulse 
conduction velocity exert an effect on the QRS width (Boulaksil et al. 2010, Wiegerinck et al. 2006). 
Both of these changes may underlie the prolonged QRS in the TAC model, since the LV mass was 
increased and there is progressive myocardial fibrosis associated with the TAC model (Huusko 
et al. 2012), which may lead to an increased conduction velocity. Instead, in healthy old mice, a 
similarly increased LV mass as found in TAC model without any signs of fibrosis resulted only 
in very minor increase in the QRS width.  
 In addition to the widened QRS and QRSp, there were repolarization abnormalities in the 
TAC model for progressive LVH. Similar changes have been found in C57Bl/6J mice in the HF 
phase of TAC model at 6-8 weeks (Speerschneider, Thomsen 2013) and in a transgenic mouse 
model of massive concentric LVH (Sysa-Shah et al. 2012). These changes resembled the secondary 
repolarization abnormalities seen in severe human LVH, which are thought to be associated with 
a poor prognosis and the progression of LVH to HF (Heikkilä, Mäkijärvi 2003, Thaler 2010, 
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TAC model for progressive LVH. Similar changes have been found in C57Bl/6J mice in the HF 
phase of TAC model at 6-8 weeks (Speerschneider, Thomsen 2013) and in a transgenic mouse 
model of massive concentric LVH (Sysa-Shah et al. 2012). These changes resembled the secondary 
repolarization abnormalities seen in severe human LVH, which are thought to be associated with 
a poor prognosis and the progression of LVH to HF (Heikkilä, Mäkijärvi 2003, Thaler 2010, 
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Schillaci, Battista & Pucci 2012). This would be interesting to study further in the TAC mouse 
model. 
The correlations between the echocardiographic and ECG measurements have not been widely 
studied in mice. A significant correlation was found between LA size and P wave duration, which 
is also seen in humans (Hazen et al. 1991), but as far as is known, this correlation has not been 
studied in mice. However, it has been shown that an increased atrial size accompanies increased 
P wave duration in a transgenic mouse model (Rosenberg et al. 2012).  There was no correlation 
between LV mass and QRS duration in healthy C57Bl/6J mice, which would have been expected 
based on the human studies (Heikkilä, Mäkijärvi 2003). Here it was seen that the increased LV 
mass per se was not sufficient to induce a prolongation of the QRS, but also other factors possibly 
inducing the prolongation of the conduction velocity, i.e. fibrosis, were needed. In addition, it 
was recently reported that the QRS duration in mice might underestimate the total ventricular 
activation time and therefore other methods in addition to surface ECG might be needed for 
validating the actual ventricular activation time (Boukens et al. 2014, Boukens et al. 2013).   
 Instead, a significant correlation was seen between the LV mass and the newly developed 
index, the QRSp duration, in normal C57Bl/6J mice. In addition, in the TAC experiment, the QRSp 
duration was possibly a more sensitive marker of hypertrophy/increase in the LV mass than the 
width of the QRS complex, since QRSp was prolonged in a more pronounced manner already at 
the 2 week timepoint, in contrast to smaller increase in the QRS width. Prolongation of the novel 
QRSp duration therefore seems to be a more sensitive marker of the LV mass increase than the 
QRS complex width. There was no correlation between the PQ interval and HR, instead, a 
significant correlation was found between HR and P wave duration, which is consistent with 
previous findings (Chaves et al. 2003). 
In summary, ECG changes seen during ageing, after pharmacological manipulations and in 
AMI and progressive LVH mouse models resembled the ECG changes seen in humans and they 
also correlated well with the echocardiographic findings. Therefore, it is concluded that the ECG 
analysis algorithm developed in this thesis is an accurate and reliable tool for analysing mouse 
surface ECG and together with the high-resolution echocardiography, it represents an accurate 
analytical method for characterizing the cardiac function in mice. With the algorithm produced 
here, it is possible to determine all the possible intervals and amplitudes of the ECG, which have 
not been reported as widely before. The analyses in the thesis produced reliable new information, 
adding to our understanding of mouse ECG and its relation to physiological and pathological 
changes in the heart;  in this way results obtained in mouse models can be better interpreted to 
clarify the underlying pathology in human cardiac diseases. 
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7 Summary and Conclusions 
In summary, in this thesis a clinically relevant high-resolution echocardiography-guided 
closed-chest intramyocardial gene transfer method was developed for mice and this method was 
used for evaluating the angiogenic potency of adenovirally delivered VEGFs and the 
transduction efficiency and safety of AdV-, AAV- and LeV vectors. In addition, a mouse ECG 
analysis algorithm was developed and validated. 
 
More precisely, the following conclusions can be made within each study: 
 
(I) The closed-chest echocardiography-guided intramyocardial injection method is a 
feasible, minimally invasive, accurate and well-tolerated method for delivering 
therapeutic genes into the mouse myocardium. After AdV gene transfer of different 
VEGFs, VEGF-B and VEGF-E were assessed as being potential candidates for inducing 
therapeutic angiogenesis; of these VEGF-B was assessed as being safer. Thus, based on 
this study, VEGF-B would be the growth factor of choice for myocardial angiogenic 
gene therapy.  
 
(II) AAV2, AAV9 and LeV vectors were less effective in transducing cardiomyocytes than 
the widely used AdV vector, but they were also less harmful in terms of myocardial 
damage and left ventricular function. Systemic administration of AAV9 was found to 
be less efficient and more harmful than intramyocardial delivery. 
 
(III) The developed ECG analysis algorithm was found to be an accurate and feasible 
method for analyzing mouse ECG. The ECG findings associated with ageing, 
pharmacological manipulations, AMI and progressive LVH correlated well with the 
echocardiographic findings and were found to resemble the ECG findings seen in 
human. 
 
 
 
Viral gene therapy with VEGF growth factors could offer new treatment possibilities for acute 
and chronic myocardial ischemia, especially for those patients in whom the current treatment 
modalities are contraindicated. The viral doses and effects of the vectors and the growth factors 
within and outside the target tissue will need to be carefully assessed in small and large animal 
models before one can progress to clinical trials. In preclinical trials, the gene transfer methods 
and the methods for analyzing cardiac function need to be as similar to the clinical setting as 
possible. Therefore, it seems likely that the results obtained in this thesis will be beneficial in the 
translation of preclinical studies into future phase I clinical trials. 
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